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ABSTRACT 
 Endophytes are bacterial or fungal organisms that live as endosymbionts in plant tissue. 
For this work, we examined fungal endophytes for their ability to inhibit bacterial, fungal and 
protozoal pathogens.   Once antimalarial activity was discovered and confirmed, we sought to 
isolate and identify the active constituent(s) of our extracts.  Bioassay-guided fractionation 
techniques were used to isolate our active compound, the structure of which was elucidated using 
1
H- and 
13
C-NMR. 2D-NMR and LC-MS analyses helped confirm that our endophytes were 
indeed producing artemisinin.  Growth versus production studies were conducted to optimize our 
growth and extraction conditions while several other variables, like temperature and culture 
medium, were evaluated in an effort to improve our yields.  Artemisinin production under both 
light and dark conditions was evaluated to determine if our production was the result of enzyme 
activity.  In addition, labeling studies were conducted using 
13
C-labeled glucose. 
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CHAPTER I 
 
THE HISTORY OF MALARIA 
 
Malaria, from the Italian mal’aira which means “bad air”, is a mosquito-borne infectious 
disease caused by a parasite of the genus Plasmodium.  From its origin in the West and Central 
Africa, malaria spread across the globe to become the most deadly disease suffered by mankind.  
The parasites spread to other areas through the journey of man, following human migrations to 
the Mediterranean, Mesopotamia, the Indian peninsula, and Southeast Asia
1, 2
.  Today, while 
seemingly nonexistent in North America, it is widespread in tropical and subtropical regions with 
the vast majority of malaria-related deaths occurring in sub-Saharan Africa.  Malaria is one of 
the most severe public health problems in many developing countries. 
The history of malaria and its effects is as ancient as the history of civilization itself.  
Malaria parasites are thought to have originated in Africa
3
.  Fossils of mosquitoes up to 30 
million years old show that the malaria vector, Anopheles mosquitoes were present well before 
the earliest history
4, 5
.  Malaria or a disease resembling malaria has been noted for thousands of 
years, with references to unique periodic fevers of malaria found throughout recorded history
6-10
.  
Early man, confronting the manifestations of malaria, attributed the fevers to supernatural 
influences like evil spirits and/or black magic.  Around 2700 B.C., several symptoms of what 
would later be named malaria were described in ancient Chinese medical writings
6, 11
. 
2 
 
Hippocrates,  regarded as the Father of Medicine, was the first to describe manifestations 
of the disease, distinguishing the intermittent malarial fever from the continuous fever of 
infectious diseases, and relating them to the time of year and to where the patients lived.  He 
noted the change in the spleen of infected individuals and was able to attribute malaria to the 
ingestion of stagnant water
12, 13
.  The association with stagnant waters, breeding grounds for the 
Anopheles mosquito, led Romans to establish drainage programs, the first intervention against 
malaria. 
While numerous theories, from Galen’s disorder in the four humors of the body to 
Lancisi’s black swamp11, 13, had been postulated early on as the cause and spread of the disease, 
it was not until the late 1870s and early 1880s that scientific studies on malaria made significant 
advances.  Charles Louis Alphonse Laveran, a French army doctor, was the first to observe and 
identify parasites as the causative agent of malaria.  He was awarded the Nobel Prize for this 
work in 1907
13
.  Although Laveran had believed there was only one species, Oscillaria malariae, 
that caused malaria, the Italian scientist Camillo Golgi (1886) established that there were at least 
two forms of the disease.  He noted that one produced fever every other day (tertian) while the 
other produced fever every third day (quartan).  Additionally he observed that the number of new 
parasites produced differed between the two forms and that the rupture and release of these new 
parasites into the bloodstream coincided with fever.  Golgi was awarded the Nobel Prize in 
Medicine in 1906 for his discoveries
4.  Shortly after Golgi’s work, Giovanni Batista Grassi and 
Raimondo Filetti first introduced the names Plasmodium vivax and P. malariae as the two 
malaria parasites that affect humans
14
.  In 1897, the name P. falciparum was given to the 
malignant, tertian malaria parasite by American William Welch
15
.  A fourth human malaria 
parasite, P. ovale, was discovered by John William Watson Stephens in the early 1920s
16
. 
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There are more than 100 species of Plasmodium, but only four of these species, P. 
falciparum, P. vivax, P. ovale, and P. malariae, infect humans
11
. 
P. falciparum, found worldwide in tropical and subtropical areas, is the only species that 
can cause severe, potentially fatal malaria.  It is estimated that 700,000 million people per annum 
are killed by P. falciparum, especially in Africa where the species predominates
11
.  Because it 
multiplies rapidly in the blood, this species can cause severe malaria and severe blood loss.  The 
infectious parasites can also clog small blood vessels which, when occurring in the brain, can be 
fatal
11
.  Today, when given prompt treatment with modern medicines, malaria resulting from P. 
falciparum is almost always curable. 
P. vivax, believed to be the most prevalent human malaria parasite, is found mostly in 
Asia, Latin America, and some parts of Africa.  Though it is geographically the most 
widespread, its symptoms are less severe. It is less virulent than P. falciparum and seldom fatal.  
While P. vivax can cause death, usually the result of an enlarged spleen it is often associated with 
debilitating but non-fatal symptoms
11
. 
P. ovale is found primarily in West Africa and the islands of the Western Pacific and it is 
biologically and morphologically similar to P. vivax, but less frequently encountered.  It is worth 
noting that both P. ovale and P. vivax exhibit a dormant stage that can persist in the liver and 
cause relapses by invading the bloodstream weeks or even years later
11
. 
P. malariae can be found worldwide and can persist in the blood for very long periods 
without ever producing symptoms.  Although also less frequently encountered, P. malariae can 
cause long-lasting, chronic infection that, in some cases can last a lifetime.  However, P. 
malariae, the so-called benign malaria is not as dangerous as the infection caused by P. 
falciparum or P. vivax
11
. 
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Around the same time other researchers were working to identify the different human 
malaria parasites, Nobel Laureate Sir Ronald Ross was working to prove the theory mosquitoes 
were responsible for the transmission of the disease to and from humans.  Ross, in 1898, showed 
that certain mosquitoes (Anopheles sp.) transmit malaria to birds by isolating malaria parasites 
from the salivary glands of mosquitoes that had fed on infected birds
13
.  Later work by Italian 
researchers provided strong evidence supporting his claims
17
.  For his work on malaria, Ross 
received the Nobel Prize in Medicine in 1902. 
By the early 1900s researchers had shown Anopheles mosquitoes to be the culprit in the 
transfer of malaria to humans.  Found worldwide, with the exception of Antarctica, anophelines 
are the only species of mosquito known to transmit malaria.  There are hundreds of species of 
Anopheles, but only a small percentage is capable of malaria transmission
1, 11
.  While different 
species can serve as transmission vectors, the common thread is that only female anophelines can 
transmit malaria.  Because these organisms serve as the primary hosts and transmission vectors 
for malaria parasites, understanding their biology and behavior has aided in our understanding of 
how malaria is transmitted and, more importantly, has proven effective in how control/treatment 
strategies can be designed. 
Like all mosquitoes, anophelines have a four-stage life cycle consisting of egg, larva, 
pupa, and adult stages.  The egg, larva, and pupa stages are all aquatic and, depending on the 
temperature and species involved, generally last 1-2 weeks.  However it is the adult stage, which 
can last up to a month, where Anopheles sp. can act as a malaria vector.  While males survive 
feeding on nectar and other sugar sources, females usually require a blood meal for development 
of their eggs.  This blood requirement, which is absent in males, is why only female anopheline 
mosquitoes transmit malaria. 
5 
 
Factors that affect the susceptibility of anopheline mosquitoes to human malaria are 
poorly understood; in fact, so too are the differences in susceptibility among various Anopheles 
sp.
18, 19 
 For those susceptible species that are capable of transmitting malaria to humans, there 
are numerous factors that affect their actual ability to do so.  Climate and survival/lifespan are 
two such factors
20
. 
Once ingested by a mosquito, malaria parasites must undergo development within the 
mosquito before they are infectious to humans.  This extrinsic incubation period ranges from 10-
21 days, with temperature and humidity playing a role in development.  However, if a mosquito 
does not survive longer than the incubation period, then she will not be able to transmit any 
malaria parasites
11
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Malaria life cycle.  Adapted from www.cdc.gov/malaria/about/biology/index.html 
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 As mentioned previously, the malaria parasite’s life cycle involves two hosts: the female 
Anopheles mosquito, which serves as the definitive host, and humans, which are intermediate 
hosts.  During a blood meal, a malaria-infected mosquito inoculates sporozoites into the human 
host.  These sporozoites, released from the mosquito’s saliva, enter the bloodstream and migrate 
to the liver.  Sporozoites infect liver cells and mature into schizonts which rupture and release 
merozoites.  Merozoites escape into the blood and infect red blood cell, thus beginning the 
erythrocytic stage of the life cycle.  Blood stage parasites are responsible for the clinical 
manifestations of the disease.  Within the red blood cells, the parasites multiply further, 
periodically breaking out of their hosts to invade fresh red blood cells.  It is this cycle of 
merozoites escaping and infecting other red blood cells that cause waves of fevers in the human 
host
11
. 
 Some merozoites turn into male and female gametocytes; these gametocytes are ingested 
by an Anopheles mosquito during a blood meal.  The parasites’ multiplication in the mosquito is 
known as the sporogenic cycle.  Fertilization and sexual recombination of the parasite occurs in 
the mosquito’s stomach, generating zygotes; this step defines the mosquito as the definitive host 
of the disease.  The zygotes develop into motile ookinetes and invade the midgut wall of the 
mosquito where they develop into oocysts.  The oocysts grow, rupture, and release sporozoites.  
New sporozoites travel to the mosquito’s salivary glands; inoculation of the sporozoites into a 
new human host perpetuates the malaria life cycle
11
. 
 The time needed for sporozoites to reach the salivary glands of the mosquito depends on 
both the species of parasite and the ambient temperature.  Plasmodium parasite development 
slows as the temperature drops
20-24
.  At 30°C, P. falciparum takes 9 days for sporozoites to reach 
the mosquito’s salivary glands; at 25°C it takes 10 days and at 20°C it takes 23 days.   
7 
 
P. vivax, at 25°C, completes the process in 9 days whereas P. malariae and P. ovale take 15 – 20 
and 16 days, respectively, at the same temperature.  For successful transmission of malaria to 
humans, the mosquitoes must live long enough for the parasite to complete its development 
within them. 
 The diseases due to all four species of malaria share the characteristic febrile episodes.  
They also have many symptoms in common with other infectious diseases including body aches, 
headache, nausea, and overall weakness.  All the typical clinical symptoms and severe disease 
pathology associated with malaria are caused by the blood stage parasite.  When the parasite 
develops in the erythrocyte numerous waste substances and toxins accumulate in the infected red 
blood cell and are released into the bloodstream when the infected cell lyse and release invasive 
merozoites.  These toxins stimulate macrophages and other cells to produce cytokines and other 
soluble factors which act to produce fevers, rigors, and likely influence other severe 
pathophysiology associated with malaria.  Untreated malaria infections are characterized by 
enlargement of the spleen.  With P. falciparum, severe and life-threatening conditions commonly 
arise, which can cause the dysfunction of vital organs like the lungs, liver, and kidneys.  In 
addition, when infected erythrocytes are sequestered in the vessels of the brain, a condition 
known as cerebral malaria is said to occur.  With cerebral malaria, infected red blood cells cause 
a blockage in the blood’s pathway resulting in a stoppage of blood flow, ultimately leading to a 
loss of oxygen and nutrients to those brain areas. Anemia is also associated with malaria 
infections and is frequently severe in children and pregnant women infected with P. falciparum, 
but can also be seen with P. vivax infection.  These are the conditions with are associated with 
most of the mortality of acute malaria
25-30
. 
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 Chronic infection with any species of malaria greatly decreases both the quality and 
duration of life.  Body tissues tend to waste away and splenic enlargement becomes a constant 
feature upon repeated attacks of the disease over the years
1
. While this is debilitating to the body, 
it also affects the mind, as infected individuals succumb to disease and/or hardships that would 
scarcely threaten a person in reasonable health. 
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CHAPTER II 
 
TREATMENT AND CONTROL STRATEGIES – Past and Present 
 
2.1 Control 
 Even in ancient times there was suspicion of a link between malaria and mosquitoes.  
From Babylonian scripts dated thousands of years ago to the writing of the Indian surgeon 
Dhanvantari to numerous Indian texts, all associated fevers with insect bites.   
Early on, man was able to establish methods for preventing malaria by protecting 
themselves from mosquitoes without seemingly making a connection between the two.  For 
example, ancient Egyptians living in the wetlands along the Nile River are reported to have set 
up barriers to prevent mosquito bites
31
.  Bed nets, designed not so much for protection against 
disease, but rather out of a desire for comfort became common in mosquito infested areas.  Yet 
one of the earliest methods was to avoid those swampy areas known to have bad air
32
.  In 
recognizing stagnant waters as a possible cause of their fevers, an observation noted by 
Hippocrates hundreds of years prior, early Roman settlers undertook the task of developing 
primitive drainage systems to relieve standing waters. 
Though there were many proponents of drainage systems, none advocated drainage as a 
solution to malaria more strongly than the Italian physician Giovanni Lancisi.   
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In his 1717 publication De Noxiis Paludum Effluviis (On the Noxious Effluvia of Marshes), 
Lancisi present the theory that malarial fevers may be caused by juices inoculated by the biting 
of insects associated with marshes.  He proposed drainage plan for marshes to eradicate malaria. 
By the end of the 19
th
 century the concept of drainage as a means of eradicating malaria 
had really taken off and numerous drainage projects had been implemented around the world
33
.  
Such drainage work contributed to a decline in malaria in the United States and parts of Europe 
by the late 1800s.  While improved sanitation helped ease the burden of malaria and some parts 
of the world, the discovery of the malaria parasite and its mode of transmission provided a basis 
for new scientific approaches towards the development of malaria control strategies.   
Researchers like Ross and S.R. Christophers, in the early 1900s, sought large-scale 
mosquito control efforts.  They organized programs to eradicate malaria in England and India 
respectively, by eliminating mosquito breeding grounds.  The goal was to clear the streets of 
trash and anything that could collect water, including puddles.  However these programs were 
met with little success.  Yet similar programs geared toward mosquito control were successful in 
other places
34
, i.e., Sir Malcolm Watson in Malaysia (1901) and William Gorgas in Havana, 
Cuba (1901). During the construction of the Panama Canal, Ross and Gorgas worked together to 
eradicate malaria and yellow fever from the Canal Zone.  Through their integrated program of 
insect and malaria control, yellow fever was eliminated and the incidence of workers requiring 
hospitalization for malaria decreased from over 80% in 1906 to approximately 10% by 1912
11
. 
In addition to improved sanitation, insecticides/pesticides were employed as weapons to 
control mosquitoes.   
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Though insecticides like pyrethrum (1901), a natural insecticide derived from the 
chrysanthemum flower, and Paris green (1920s), a mixture of diesel oil and copper acetoarsenite, 
were successfully used to control malaria early on, dichlorodiphenyltrichloroethane (DDT) 
remains one of the most well-known insecticides used in malaria control (Fig. 2).  Although first 
synthesized during the 1870s, it was not until 1939 that the insect killing properties of DDT were 
discovered.  Paul Müller was created with this discovery, for which he was awarded the 1948 
Nobel Prize in Physiology and Medicine
4
.  DDT was used extensively during World War II to 
control malaria and was met with much success.  After the war, around 1945, DDT was made 
available to farmers as an agricultural insecticide
35
.   
 
Figure 2: Structure of DDT 
 
 
While malaria had already been brought under control in the United States, mainly through 
sanitation efforts which helped limit mosquito breeding grounds and the use of screens around 
houses to protect against mosquitoes, DDT served to prevent re-introduction of malaria from 
troops returning home. 
Relying largely on DDT, the World Health Organization (WHO), in 1955 launched a 
global malaria eradication campaign; the goal of which was to eliminate malaria through vector 
control.  The program was successful at eliminating malaria in areas where infection and/or 
transmission rates were already low (i.e., North America, Europe, Russia, etc.). However, in 
regions with high rates of transmission and poor infrastructure, the program failed
11
.   
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The failure in part was due to the uniform eradication strategy the program imposed for all 
countries and areas without regard to the diversity of the disease.  Designed to have a limited 
duration to prevent the development of mosquito resistance to DDT, the program did not adhere 
to the prescribed limits in high transmission areas.  This led to widespread resistance
36
.  Research 
showed that due to its poor infrastructure, the program was never applied in sub-Saharan Africa, 
an area in which over 90% of annual malaria deaths occir.  In 1969, with many regions still 
battling malaria, WHO ended its global eradication campaign due in part to resistance as well as 
a lack of funding.  In 1972, the Environmental Protection Agency (EPA) banned the use of DDT 
due to its negative environmental impacts
37
. 
 
2.2 Treatment 
Galen, an ancient Greek physician, believed malarial fevers were caused by corrupt body 
humors and suggested that the normal hormonal balance should be restored by bleeding and/or 
purging
38
.  This practice was accepted for the next 1500 years, with very little success.  
Ironically, it was those who could not afford the help of the medical profession that managed to 
survive. 
 Although malaria was widespread and common, European physicians found no truly 
effective treatment until around the 17
th
 century.  In the 1630s Antonio de Calancha, an 
Augustinian monk, published a notice regarding its treatment.  It read: “A tree grows which they 
call ‘the fever tree’ in the country of Loxa, whose bark, of the color cinnamon, made into powder 
amounting to the weight of two small silver coins and given as a beverage, cures fevers and 
tertiana; it has produced miraculous results in Lima
39.”  Calancha was describing the bark of the 
cinchona tree.  As the use of cinchona spread, chemist began to search for the active ingredient 
of the bark.   
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In 1820, quinine was isolated and quickly became the treatment of choice for intermittent fevers 
later discovered to be associated with malaria.  Despite isolated incidences of resistance, quinine 
remains an important and effective treatment for malaria in most parts of the world
40
. 
 Due to the lack of quinine readily available for troops during the war, antimalarial drug 
development flourished after the First World War as many new drugs were developed to protect 
troops from malaria (Fig. 3). Pamaquine (1926), the first synthetic malaria drug, was an 8-
aminoquinmoline.  While it showed promise, associated toxicities limited its efficacy
41
.  
 
Figure 3:  Antimalarial drugs currently used in the treatment of malaria. 
 
 
Developed in 1932, the 9-amino-acridine mepacrine was also designed as a quinine substitute.  
Although undesirable side effects halted its use as an antimalarial, mepacrine is still used in other 
clinical applications. The synthesis of the breakthrough drug chloroquine in 1934 led to a new 
class of agents known as the 4-aminoquinolines
42
.   
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Post World War II, chloroquine became one of the principal treatments in the global control of 
malaria.  The efficacy and affordability of chloroquine, along with the invention of DDT, 
provided the tools needed to control and potentially eradicate malaria in both human and 
mosquito hosts.  However a little more than a decade or so after its emergence as a weapon 
against this pandemic threat, chloroquine resistance appeared in P. falciparum and began to 
spread across the globe
43
.  More recently chloroquine resistance in P. vivax has been noted
44
. 
 The success of chloroquine led to the exploration of many other compounds in the United 
States.  Other 4-aminoquinolines like Camoquine (1946) were discovered.  Although it is not 
marketed in the United States, early studies showed Camoquin to be more effective against some 
P. falciparum strains than chloroquine
45, 46
.  In addition, studies on 8-amnioquinolines led to the 
discovery of Primaquine (1950), a structural analog of pamaquine.  Primaquine is used in the 
treatment of latent P. vivax and P. ovale liver parasites.  At the same time British researchers, in 
their extensive study of malaria drugs, synthesized the antifolate drugs (Fig. 4) proguanil (1944) 
and pyrimethamine (1952).  Resistance to these antifolates appeared within a year of their 
introduction.   
 
Figure 4:  Antifolate drugs used in to treat malaria 
 
 
During the 1960s, the Walter Reed Army Institute of Research (WRAIR) was the primary 
source of support for malaria research.  While the program provided support for various projects, 
drug discovery was their first priority.    
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Over 100 compounds were produced at WRAIR in an effect to find an alternative to quinine.  
Mefloquine (1971), a 4-quinoline methanol developed jointly by the United States Army and 
several other agencies, proved useful for the U.S. Army in Southeast Asia and South America in 
treating and preventing resistant P. falciparum (Fig. 5).  Data showing the efficacy of 
Mefloquine against P. falciparum was first reported in 1974.  However evidence of resistance to 
mefloquine began to appear in these areas by the time in became widely available in 1985. 
 
Figure 5:  Mefloquine 
 
 
While combination therapies like malarone (1998) which combines the antifolate 
proguanil with atovaquone, a drug approved in 1992 for the treatment of Pneumocystis carrinii, 
have improved the efficacy of previously resistant drugs, artemisinin is, today, emerging as a 
very potent and effective antimalarial agent. 
 The herb Artemisia annua or sweet wormwood has long been known to the Chinese as 
qinghao and has been used in the treatment of many illnesses.  Although its antimalarial 
properties were first described by Ge Hong many centuries ago, research on Artemisia did not 
begin until the late 1960s.  The project was set up in an effort to find a suitable treatment for 
malaria.  Artemisinin was discovered in the early 1970s by a Chinese scientist.   
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Found in the leaves of Artemisia annua, artemisinin was just as effective as quinine and 
chloroquine at clearing the malaria parasite.  Today many active artemisinin derivatives have 
been synthesized and while tolerance has been noted, no resistance to these drugs has been 
reported
47
. 
 
2.3 Shortcomings of Current Treatment Strategies 
It is evident that much research has been done in combating malaria and much progress 
has been made.  However drug resistance continues to be a significant problem in the fight 
against malaria.  Studies have shown that chloroquine resistance emerged from two independent 
loci in South America and Southeast Asia
48-50
 and spread across the globe.  Resistance renders 
once effective drugs obsolete.  The loss of chloroquine efficacy has had a considerable impact on 
the treatment of malaria as the most effected countries are also the most resource poor and 
chloroquine was an affordable treatment option
51
.  Antimalarials released since the emergence of 
chloroquine resistance have met a similar fate. With resistance to all classes of antimalarial 
drugs, with the exception of the artemisinins, now common, the problem of treating malaria is 
even more complex
47
.  What is even more troubling is that new evidence suggests the emergence 
of malaria strains that are resistant to artemisinin combination therapies
52
.  The spread of such a 
strain would be detrimental to treatment efforts as it would not be treatable with any other 
currently available therapeutics.   
Despite the shrinking pool of effective antimalarial therapies, new antimalarial drug 
development has only occurred in the last decade or so
53, 54
.  As a result, almost all antimalarials 
on the market were synthesized or discovered during the efforts around the two world wars; new 
agents are desperately needed.   
17 
 
Yet, what is clear from the history of agents used to treat malaria is that plant-derived drugs have 
far outlived synthetic drugs which are prone to the development of resistance.  If history is at all 
indicative of the future, the value of natural product-derived antimalarials cannot be 
underestimated. 
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CHAPTER III 
 
THE DISCOVERY AND BIOSYNTHESIS OF ARTEMISININ 
 
3.1 Discovery of Artemisinin 
Known also as qinghaosu, artemisinin was isolated from the leaves of the Chinese 
medicinal plant A. annua L. in the 1970s.  Administered in combination with other antimalarials, 
artemisinin and its derivatives are now the current treatment of choice for drug resistant malaria 
caused by P. falciparum. 
 
 
Figure 6:  The plant Artemisia annua L. (photo by Peter Griffee taken in Jingxi County, China) 
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A. annua or sweet wormwood (Fig. 6), is an annual herb native to Asia; in China it is 
known as qinghao.  The plant has become naturalized throughout the world.  As early as 350 
AD, the herb was mentioned in Chinese medical literature for the treatment of fevers
55
.  
However it was not until 1971 that Chinese scientists isolated a compound with antimalarial 
properties from A. annua, a discovery that can be attributed to a program launched by the 
Chinese government in search of new antimalarials from plants used in traditional Chinese 
medicine.  Extraction of the aerial parts of the plant yielded a compound mixture that was shown, 
in animal models, to have antimalarial activities
56
.  The active constituent, artemisinin (or 
qinghaosu as it referred to in Chinese) was isolated from the mixture; within a year its structure 
was elucidated via X-ray analysis
57
, with structural assignments later verified by NMR
58
.  
Clinical studies using the purified artemisinin showed that in P. vivax and P. falciparum infected 
patients it killed the parasite early in its life cycle.  More noteworthy was the drug’s effectiveness 
against chloroquine- resistant P. falciparum
56
. Though identified in 1972, data related to the 
discovery of artemisinin was not made public until 1979
59
.  Even with the immense promise the 
drug showed, it was still nearly a decade before artemisinin gained global access, although this 
was not for a lack of trying.  Many international organizations showed interest and those like the 
WHO, who were fully capable of developing the drug, were denied access to both the drug and 
the herb itself by the Chinese government as they did not trust the intentions of the Western 
world. 
 Chemically, artemisinin is a sesquiterpene lactone with an endoperoxide bridge.  Noting 
the instability associated with the 1, 2, 4-trioxane ring functionally embedded in the structure, 
some questioned the usefulness of artemisinin as a drug.  However, current data suggests this to 
be the basis for the drug’s antimalarial activity60, 61.   
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It has been proposed that the endoperoxide linkage, in the presence of the parasite, triggers the 
action of the drug.  When it comes in contact with iron (II), the endoperoxide bond is cleaved, 
releasing reactive radicals which ultimately destroy the parasite.  Yet as effective as it had the 
potential to be, artemisinin is limited by its poor water and oil solubility.  This was also noted by 
the Chinese scientists during the drug discovery process.  When hot water was used to extract A. 
annua, the extracts were shown to have no antimalarial activity in animal models; however they 
were able to obtain active extracts when cold ether was used to extract the plant.  In an effort to 
improve the solubility of artemisinin, hundreds of semi-synthetic derivatives were developed.  
Some success was seen from exploitation of the lactone, resulting in the drugs artemether, a 
methyl ether derivative; arteether/artemotil, an ethyl ether derivative; and artesunate, a succinate 
ester derivative (Fig. 7).  
 
Figure 7:  Artemisinin and some of its derivatives 
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These derivatives all have greater potency than the parent drug artemisinin.  In addition, 
solubility is improved.  Artemether and arteether are both oil soluble and are rapidly metabolized 
to dihydroartemisinin in vivo.  Artesunic acid is water soluble and can be delivered more quickly, 
making it more effective in the treatment of advanced malaria cases.  The water soluble 
derivative is hydrolyzed more rapidly than it oil soluble counterparts due to the unstable hemi-
ester linkage.  Current malaria treatment therapy is based on formulations from these derivatives, 
with production relying entirely on extraction of artemisinin from A. annua as it is currently the 
only known source. 
 
3.2 Biosynthesis of Artemisinin 
 While there is no universally accepted route for the biosynthesis of artemisinin in A. 
annua, it is expected to involve the mevalonate pathway and include the cyclization of 
farnesyldiphosphate (FPP)
62
.  Though more recent work suggests that the isopentyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) precursors for FPP come from 
both mevalonate and non-mevalonate pathways
63
.  Others have shown that the central isoprenoid 
unit in the FPP precursor is predominately biosynthesized from the non-mevalonate/1-deoxy-D-
xylulose 5-phosphate (DXP) pathway
64
. 
 The first step in the biosynthesis of artemisinin involves the conversion of IPP and 
DMAPP to FPP, a C15 intermediate.  This conversion is catalyzed by the enzyme 
farnesyldiphosphate synthase (FPPS)
62, 65
.  
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Figure 8:  Biosynthesis of FPP precursor. 
 
The formation of the bicyclic sesquiterpene skeleton (Fig. 9), amorpha-4,11-diene results from 
the action of amorpha-4,11-diene synthase (ADS), which catalyzes the cyclization of FPP
66, 67, 68, 
69
. 
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Figure 9:  Biosynthesis of amorpha-4,11-diene. 
 
 While cDNAs encoding FPPS
68 
and ADS
69-71 
have been isolated from A. annua 
supporting the early steps, the route to artemisinin beyond amorpha-4,11-diene is a bit hazy.  
Evidence for two potential pathways for amorpha-4,11-diene to the final artemisinin precursor is 
supported throughout the literature.   
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Early on it was assumed and widely accepted that the biosynthetic route from amorpha-4,11-
diene involved oxidation of the isopropylidene group to yield artemisinic alcohol, which was 
oxidized to artemisinic aldehyde.  Artemisinic aldehyde was then oxidized to artemisinic acid, 
the widely accepted final precursor to artemisinin
72
.  Work by Teoh et al.
73
 (2006) lends support 
to such a pathway as they were able to isolate a key cytochrome P450, CYP71AV1, from A. 
annua.  Using amorpha-4, 11-diene as a substrate, CYP71AV1 was shown to catalyze the three 
successive oxidations required to go from amorpha-4,11-diene to artemisinic acid (Fig. 10). 
 
Figure 10:  Oxidation of amorpha-4,11-diene to artemisinic acid. 
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Additionally, the enzyme was found to be inactive on other mono- and sesquiterpenes.  Similar 
conclusions were drawn by Ro et al.
74
 (2006) who showed that when CYP71AV1 was co-
expressed in yeast with the genes required for amorpha-4,11-diene biosynthesis, artemisinic acid 
was formed.  However, Teoh et al. (2006) also observed that CYP71AV1, in vitro performed 
predominately single oxidations, suggesting that CYP71AV1 products may be released after a 
single oxidation.  This, along with more recent work implicates dihydroartemisinic acid as the 
final precursor in artemisinin biosynthesis.  Previous studies have concluded that the C11-C13 
double bond of artemisinic acid could be reduced yielding dihydroartemisinic acid; however, 
separate labeling studies conducted by Brown and others suggest that artemisinic acid is not 
converted to dihydroartemisinic acid
75 
nor is dihydroartemisinic acid converted to artemisinic 
acid
76 
in A. annua.  Using labeled artemisinic acid, Brown’s in vivo study found no incorporation 
of the label into artemisinin; this varied from early literature that reported direct conversion of 
artemisinic acid into artemisinin using cell free systems
65, 77-80. However, Brown’s work is 
consistent with more recent reports concluding that dihydroartemisinic acid is the final precursor 
in the biosynthesis of artemsinin
72, 73, 76, 81, 82
 as the data showed, using labeled 
dihydroartemisinic acid, it is incorporated in artemisinin.  Bertea et al.
72
 (2005) concluded that 
dihydroartemisinic acid is derived from artemisinic alcohol via oxidation at C12 and reduction of 
the C11-C13 double bond to yield dihydroartemisinic aldehyde. Dihydroartemisinic aldehyde 
then undergoes further oxidation to dihydroartemisinic acid. 
 Taking more recent studies into account, it is assumed that dihydroartemisinic acid, rather 
than artemisinic acid, is the final precursor in the biosynthesis of artemisinin.  To date however, 
there is no in vivo data to support the biosynthetic steps by which dihydroartemisinic acid is 
converted to artemisinin.   
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The conversion is believed to proceed non-enzymatically as no enzymes have been identified for 
such a process.  Brown, along with others
83, 84
, has reported data supporting the notion of 
spontaneously occurring chemical reactions.  It has been proposed that the primary route for 
transformation of dihydroartemisinic acid is by auto oxidative reaction of the C4-C5 double bond 
with singlet oxygen (
1
O2) which yields a tertiary allylic hydroperoxide.  Ring expansion via 
Hock cleavage of the hydroperoxide followed by a second oxygenation of the resulting enol 
product and cyclization of the vicinal hydroperoxyl-aldehyde to the 1, 2, 4-trioxane of 
artemisinin (Fig. 11). 
 
 
Figure 11:  The biosynthesis of artemisinin using dihydroartemisinic acid as the final precursor. 
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CHAPTER IV 
 
THE RESEARCH PROJECT 
 
4.1 Fungal Endophytes 
Fungi are a group of eukaryotic organisms that includes mushrooms as well as yeasts and 
molds.  They are abundant worldwide, living in soil, on dead matter, and in symbiotic 
associations with plants, animals, and even other fungi.  An endophytic fungus is one that lives 
within plant tissues without causing immediate harm to the plant.  These symbiotic relationships 
are ubiquitous in nature yet they are not very well understood.  What are of interest to the 
pharmaceutical industry are the numerous secondary metabolites produced from these plant-
endophyte interactions, some of which have been used to produce drug agents.  The most notable 
fungal endophyte, from a medicinal standpoint, is Taxomyces andeanae.  In data reported by 
Strobel and colleagues
85
 (1993), T. andeanae, an endophytic fungus associated with the Pacific 
Yew (Taxus brevifola), was observed to produce the anti-tumor agent taxol.  While fungi 
themselves produce a huge variety of natural products that range from toxic metabolites that can 
be deadly if consumed to pharmaceutical drugs like penicillins whose biological activity has 
resulted in many lives saved.  Indeed numerous fungal species are routinely employed as 
medicinal agents in clinical settings.  They can be used to treat viruses, bacterial infections, and 
even cancerous cells
86-89
.   Still the need for new medicinal agents for the treatment of various 
diseases necessitates exploration of new horizons.   
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Although it has been reported that every plant species in existence hosts at least one endophyte
90
, 
only a few of these interactions have been studied.  Because there are so many of them 
occupying so many unique plants, endophytes have the potential to be great sources of bioactive 
natural products, as natural products and the organisms that make them, offer tremendous 
opportunities for drug discovery. 
  
4.2 Collection and Extraction of Fungal Endophytes 
Endophyte isolation and extraction procedures were conducted and followed the 
established methods developed by Arnold and others
91, 92, 93
.
 
 Sample collection took place at two 
sites, one a relatively dry location near the University of Arizona (32.231°N, 110.952°W, 
elevation 787m; mean annual temperature = 20.2°C), receiving an average of 30.5cm of 
precipitation annually.  The other site, located in Durham, NC (36.001°N, 78.940°W, elevation 
97m; mean annual temperature = 15.5°C), was a more moist habitat, receiving an average 
109.2cm of annual precipitation.  Small stem pieces bearing mature foliage and samples from 
healthy roots were removed from each focal plant and placed in sealed plastic bags after excess 
moisture was removed.  Plant materials remained on ice at ~4°C until they were transported to 
the laboratory; endophytes were isolated within 4 hours of collection.  Prior to surface 
sterilization, the plant tissue samples were rinsed in running water and then cut into 2mm pieces.  
The plant fragments were then sterilized with sequential immersion in 95% ethanol (30s), 10% 
bleach (2min), and 70% ethanol (2min) to eliminate contaminating microbes and then surfaced-
dried in a sterile environment.  Surface tissue was removed and the remaining tissue was 
macerated and streaked in small aliquots on malt extract agar (MAE) plates which encourage the 
growth of diverse fungal cultures
94
.  Cultures were incubated at room temperature under ambient 
lighting conditions with growth monitored daily over an eight week period.   
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Morphologically unique fungal colonies were isolated and sub-cultured on MAE plates which 
were allowed to grow for one week.  Additionally, impressions of some tissue fragments were 
made by pressing them against the medium (MAE) and removing them after 30s.  As this was 
done to confirm the effectiveness of the surface sterilization procedure; no mycelial growth was 
observed from the impressions.  Each isolate was vouchered for long-term storage by suspension 
of mycelia and conidia in sterile water.  Vouchers are maintained as part of a permanent 
collection of living endophyte cultures at the Robert L. Gilbertson Mycological Herbarium at the 
University of Arizona where they are archived for future use. 
 
4.3 DNA Extraction and PCR 
 All representative fungi were genotyped using high-throughput methods developed by 
Arnold
95
 using the nuclear ribosomal marker Internal Transcribed Spacer (ITS) rDNA.  Genomic 
DNA was extracted from each isolate using mycelium taken from the active culture.  Using a 
sterile pestle, the mycelium was ground in 500l SDS extraction buffer (0.15, NaCl, 50mM Tris 
[pH 8.0]; 10mM Na2EDTA; and 2% SDS).  The samples were incubated 12 hours at room 
temperature, after which they were treated with 500l of phenol:chloroform:isoamyl alcohol 
extraction mixture; reaction tubes were centrifuged at 10000G for 15mins.  The DNA was 
precipitated from the resulting supernatant using -20°C absolute isopropanol and the reaction 
tubes were again centrifuged at 10000G (5mins).   The pellet resulting was washed in 70% 
ethanol (EtOH) kept at -20°C, dried in a rotary vacufuge for 40mins to concentrate the DNA, and 
then eluted in 50l of sterile water.  The extracted DNA was diluted 1:10 for use in PCR. 
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PCR amplification of the nuclear ribosomal internal transcribed space region (ITS rDNA) 
called for reactions of 2.5l dNTPs (10M), 2.5l bovine serum albumin (BSA), 2.5l PCR 
buffer, 1.25l of each primer (ITS5 or ITS1F and ITS4 or LR3, 10M), 13.875 l water, 0.125l 
of Taq polyermase, and 1.0l of diluted template.  The PCR reactions were initialized at 95°C 
for 4mins; this was followed by 35 thermal cycles of 95°C for 30s, 50°C, 52°C, or 54°C for 30s, 
and 72°C for 90s for denaturation, annealing, and elongation respectively.   The reactions were 
held 10mins at 72°C for final elongation.  After visualization on 1% agarose gels, the PCR 
products were cleaned (Qiagen PCR Purification Kit) and sequenced for both forward and 
reverse reads using the primers ITS4, ITS5, or ITS1F at the University of Arizona Genomics and 
Technology Center.  The sequencing was performed on an ABI 3700 automated sequencer.  
Resultant sequences were compared against a database of more than 3500 ITS rDNA sequences 
maintained by Arnold, as well as against existing records in GenBank database for putative 
identification of the endophytes.   
 
4.4 Growth and Extraction of Endophytes 
The endophytic fungi were supplied to us stored in sterile water.  To revive the isolates, 
100l of each of the stock isolates was taken, using sterile techniques, and pipetted onto nutrient 
agar plates.  These plates were incubated at room temperature (~25-30°C) for 14 days with daily 
growth monitoring.  After the prescribed growth period, plates were refrigerated to retard further 
growth.  The fungal organisms were subsequently transferred to Potato Dextrose Agar (PDA) 
slants where there were grown and maintained.  A sterile loop was used to transfer fungal 
colonies of those isolates exhibiting growth on PDA into Potato Dextrose Broth (PDB).   
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For small scale extractions isolates were inoculated into 50ml PDB contained in 125ml conical 
flasks; large scale extractions called for a 1L volume of PDB, for which 2800ml Fernbach flasks 
were used.  The opening of the flasks was covered with aluminum foil and then incubated, with 
shaking at 140 rpm (160 rpm for large scale extractions), for 14 days at 30ºC.  The broth cultures 
were extracted as presented in Figure 12.  The broth cultures were first filtered through sterile 
cotton using vacuum filtration; the resulting supernatant was extracted in an equal volume of 
ethyl acetate (EtOAc), with aqueous and organic layers allowed to separate after vigorous 
shaking.  The organic layer was removed, while the aqueous layer was twice more extracted 
(v/v) with EtOAc.  
 
Figure 12:  Extraction of cultures. 
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The organic layers from the three extractions were pooled in a round bottom flask and 
evaporated to dryness using a Büchi Rotavapor R-200 with a water bath temperature of 40ºC.  
The remaining residue represented the crude extract, of which, ~10mg was submitted for assay 
screening.  The extracts were submitted for antimicrobial and antiprotozoal assay analyses 
because the assays would be run in house here at the University of Mississippi.  Furthermore, 
since there was no biological data already available for any of the organisms, it was best to 
submit them for all assays so as to assess their full spectrum of activity. 
 
4.5 Assay Screening 
4.5a. Antimicrobial Assay
96 
 The antimicrobial assay includes both antibacterial and antifungal bioassays.  The 
organisms tested include the fungi Candida albicans, Cryptococcus neoformans, and Aspergillus 
fumigatus and the bacteria methicillin-resistant Staphylococcus aureus (MRS), Escherichia coli, 
Pseudomonas aeruginosa, and Mycobacterium intracellulare; all of which were obtained from 
the American Type Culture Collection (ATCC).  With the exception of A. fumigatus, long-term 
storage of strains is accomplished by freezing the broth cell cultures in 10% glycerol at -70°C.  
While fresh slants or plates of M. intracellulare and A. fumigatus are prepared from frozen 
stocks every 4 – 5 weeks, those for all other organisms are prepared 3 – 5 days before each 
assay.  In preparation of fresh cultures C. albicans is incubated on Sabouraud Dextrose agar 
plates for 18 – 24 hours at 37°C and C. neoformans is incubated at 30°C for 72 hours.  MRS, E. 
coli, and P. aeruginosa are all incubated on Eugon agar plates for 18 – 24 hours at 37°C; M. 
intracellulare is incubated on Lowenstein – Jensen agar slants for 1 week at 37°C and A. 
fumigatus is incubated on YM agar slants for 3 – 5 days at 30°C.  These temporary cultures (for 
immediate use in assay) are stored at 4°C until needed.   
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Other than M. intracellulare, which is tested using a modified method of Franzblau et al.
97
, 
susceptibility testing is performed using a modified version of National Committee for Clinical 
Laboratory Standards (NCCLS) methods
98-101
.  DMSO solutions of samples to be tested are 
serially diluted in saline and transferred in duplicate to 96 well microplates.  The microbial 
subcultures are prepared and diluted in broth to reach the desired colony forming units (CFU) per 
milliliter.  The microbial inocula are added to the samples to achieve a final volume of 200l and 
final test concentration of 50g/ml for crude extracts and 20g/ml for pure compounds.  Growth 
(saline only), solvent, and blank (media only) controls are included on each test plate.  Drug 
controls, Ciprofloxacin (bacteria) and Amphotericin B (fungi) are included in each assay.  Plates 
are read using either optical density at 630 nm using the EL – 340 Biokinetics Reader (Bio – Tek 
Instruments, Vermont) or fluorescence at 544ex/590em (M.intracellulare, A. fumigatus) using 
the Polarstar Galaxy Plate Reader (BMG LabTechnologies, Germany) prior to and after 
incubation.  Percent growth is calculated and plotted versus the test concentration to provide the 
IC50, which is the sample concentration that imparts 50% growth of the organism.  The minimum 
inhibitory concentration (MIC), lowest test concentration that allows no detectable growth, is 
determined only for pure compounds. 
 
4.5b. Antimalarial Assay
96 
 Anti-malarial assays were conducted by the National Center for Natural Products 
Research at the University of Mississippi.  The bioassays have been developed to handle the 
testing of crude natural product extracts, extracts from fractionation, and purified compounds.  
The 96 well microplate assay is based on evaluation of the effect of compounds/extracts on 
growth of asynchronous cultures of P. falciparum, determined by the assay of parasite lactate 
dehydrogenase (pLDH) activity. 
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 Anti-malarial activity in the extracts and purified natural products was determined in 
vitro on chloroquine sensitive (D6, Sierra Leone) and resistant (W2, IndoChina) isolates of 
Plasmodium falciparum.  The appropriate dilutions of the compounds/extracts were prepared in 
DMSO or RPMI-1640 medium and added to cultures of P. falciparum (2% hematocrit, 2% 
parasitemia) set up in clear flat bottomed 96 well plates.  The plates were placed into a 
humidified chamber and flushed with a gas mixture of 90% N2, 5% CO2, and 5% O2.  They 
cultures were incubated at 37°C for 48 hours.  Growth of the parasite in each well is determined 
by pLDH assay using Malstat® reagent.  The medium and RBC controls were also set up in each 
plate.  The standard anti-malarial agents chloroquine and artemisinin were tested as the positive 
controls while DMSO was tested as the negative control. 
 For primary screening the crude extracts/fractions were tested at a single concentration of 
15g/ml only on chloroquine sensitive (D6) strain of P. falciparum.  The extracts showing >50% 
inhibition in the growth of the parasite were subjected to secondary screening at three 
concentrations and, if necessary, to tertiary screening at six concentrations for determination of 
IC50 values.  All compounds were simultaneously tested for cytotoxicity on VERO (monkey 
kidney fibroblast) cells by Neutral Red assay.  The IC50 value for each test sample was computed 
from the growth inhibition curve. 
 
4.5c. Leishmania Assay
96 
 In vitro testing for anti-leishmania activity is done using a culture of Leishmania 
donovani promastigotes.  Assay compounds, with appropriate dilutions, are added to the 
leishmania promastigotes or the axenic amastigotes cultures containing 2 x 10
6 
cells/ml.   
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The plates are incubated at 26°C for 72 hours; growth of lesimania promastigotes/axenic 
amastogotes is determined by alamarBlue® Assay.  With Pentamidine and Amphotericin B used 
as standards, the IC50 and IC90 value for each extract/compound is computed from the growth 
inhibition curve. 
4.4d. Cytotoxicity Assay
102 
 The in vitro cytotoxicity activity of compounds is determined up to a highest 
concentration of 10mg/ml against VERO and pig kidney epithelial cells (LLC-PK11) obtained 
from American Type Culture Collection (ATCC, Rockville, MD).  The assay is performed in 96 
well tissue culture-treated microplates.  Cells were seeded at a density of 25,000 cells/well and 
incubated for 24 hours.  Samples at different concentrations were added and plates were again 
incubated for 48 hours.  The number of viable cells was determined using Neutral Red according 
to a modification of the procedure of Borenfreund and Babich
103
.  IC50 values were determined 
from dose response curves of percent growth inhibition against test concentrations.  Doxorubicin 
was used as a positive control while DMSO was used as a negative (vehicle) control. 
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CHAPTER V 
 
THE RESEARCH PROJECT – Data 
 
5.1 Preliminary Data 
 5.1a. Antibacterial and Antifungal Data 
 
TABLE 1: ANTIMICROBIAL ACTIVITY REPORT – PRIMARY (Data Set 1) 
 % Growth Inhibition
1,2
 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
fumigatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9188 10 8 12 70 0 0 0 9 3 18 
DC657 0 3 16 24 5 0 1 9 7 0 
DC018 0 0 4 0 1 0 0 11 6 0 
9295 0 0 7 0 2 0 1 1 0 0 
6249 20 21 39 82 38 6 5 29 2 18 
DC509 20 21 32 80 94 3 0 13 4 0 
9116 13 27 46 87 43 4 2 42 0 21 
6063 18 22 35 88 39 5 1 25 0 21 
6139 0 2 12 19 3 3 1 8 5 0 
DC012 7 4 22 28 6 0 5 5 5 62 
DC399 0 0 4 2 3 0 0 0 5 0 
9054 0 3 3 0 1 0 5 0 2 0 
DC376 20 13 22 88 27 0 0 10 7 0 
9247 0 18 23 85 33 6 0 21 7 21 
DC7 22 20 23 71 71 0 0 34 6 0 
6262 22 22 24 83 39 5 2 32 3 22 
Concentration: 50g/ml 
1Samples showing % Growth Inhibition < 50 are considered inactive  
2Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
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While data shows that the extracts were inactive against most of the microorganism under 
study (growth inhibition less than 50%), some extracts (highlighted in red above) did show 
activity (greater than or equal to 50% growth inhibition) against C. neoformans, a yeast 
associated with lung infections as well as fungal meningitis. A. fumigatus, a fungus that is known 
to cause a range of diseases generally termed aspergillosis in immunocompromised individuals; 
and M. intracellulare, a bacterium known to cause pulmonary disease (Table 1).  Those extracts 
showing activity were moved forward for secondary assay screening. 
 
TABLE 2: ANTIMOCROBIAL ACTIVITY REPORT – SECONDARY (Data Set 1) 
 
*
IC50 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
fumigatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9188 - - >50 - 38.90 - -  - - 
6249 - - >50 29.34 3.54 - -  - - 
DC509 >50 - >50 14.94 5.01 - -  - - 
9116 >50 - >50 <2 >50 - -  - - 
6063 >50 - >50 <2 >50 - -  - >50 
DC012 >50 - 45.13 50.00 - - -  - 39.87 
DC376 - - 24.00 <2 >50 - -  - - 
9247 - - 28.86 <2 - - -  - - 
DC7 - - 50.00 16.81 7.30 - -  - - 
6262 - - 15.94 <2 >50 - -  - - 
“-“ = Not Active 
Concentration:  50, 10, 2g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
Microorganism Drug Control IC50 (g/ml)
* MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.20 0.63 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.25 0.63 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.51 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.10 2.50 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.42 0.63 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.17 0.50 
Methicillin-resistant S. aureus ATCC 43300 (MRS) Ciprofloxacin 0.09 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.006 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.082 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.36 0.50 
 
38 
 
 In secondary assay screening, the extracts were tested at three concentrations (50, 10, and 
2g/ml).  The IC50 values reported here represent the concentration (g/ml) that affords 50% 
growth inhibition (Table 2). Of those samples for which an IC50 value could be attained, none 
were an improvement over the drug control for that particular organism.  Those samples whose 
IC50 was less than the lowest concentration tested (<2g/ml) were retested at lower 
concentrations. 
 
 
TABLE 3: ANTIMOCROBIAL ACTIVITY REPORT – TERTIARY (Data Set 1) 
 
*
IC50 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
fumigatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9116 - - 19.80 1.20 - - -  - - 
6063 - - 29.49 0.53 - - -  - - 
DC376 - - 45.97 1.34 - - -  - - 
9247 - - 43.08 4.50 - - -  - >50 
6262 - - >50 0.73 - - -  - - 
“-“ = Not Active 
Concentration:  50, 10, 2, 0.4, 0.08, 0.016g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
Microorganism Drug Control IC50 (g/ml)
* MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.22 1.25 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.29 0.63 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.69 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.18 2.50 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.35 0.63 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.11 0.25 
Methicillin-resistant S. aureus ATCC 43300 (MRS) Ciprofloxacin 0.09 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.004 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.066 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.33 0.50 
 
 
 In the tertiary assay, six concentrations were tested, the lowest being 0.016g/ml.  The 
IC50 values are expressed in Table 3.  While still significant, none of the reported IC50 values 
were less than that of Amphotericin B, the drug control for C. neoformans testing. 
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In Table 4, we again see that the extracts were inactive against most of the 
microorganism under study, with only one showing any activity against the fungal pathogen A. 
fumigatus.  All extracts tested in this batch showed activity against C. neoformans.   
Half of the extracts tested here showed 50% or better growth inhibition of Candida krusei, which 
can colonize and infect different areas of the body.  At least one isolate showed inhibitory 
properties against bacterial, intestinal pathogen Escherichia coli, with another showing disparate 
activity.  Extracts showing activity were subjected to secondary assay screening. 
 
 
TABLE 4: ANTIMICROBIAL ACTIVITY REPORT – PRIMARY (Data Set 2) 
 % Growth Inhibition
1,2
 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
fumigatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9191 27 21 43 77 11 0 0 34 0 23 
2380 29 24 44* 77 21 0 0 45 0 25 
9298 24 17 50 76 15 0 1 38 0 25 
DC22 28 32 50 76 14 0 0 50* 0 0 
DC004 26 26 46 75 99 0 0 55 14 0 
DC038 25 27 41 70 18 0 0 48 1 24 
DC299 29 26 51 68 18 0 6 37 8 0 
2123 27 14 56 65 10 0 0 44* 1 21 
Concentration: 50g/ml 
1Samples showing % Growth Inhibition < 50 are considered inactive  
2Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 NOTE: * indicates a sample with disparate data 
 
Table 5 displays the secondary assay data; the lowest test concentration here was 2g/ml.  
IC50 values were reported for all organisms under study, with the exception of C. neoformans as 
the IC50 for each extract was lower than the lowest tested concentration.  None of the IC50 values 
reported here were improvements over the drug control for that particular organism; however, all 
isolates were tested further as there IC50 against C. neoformans had not yet been attained.   
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TABLE 5: ANTIMOCROBIAL ACTIVITY REPORT – SECONDARY (Data Set 2) 
 
*
IC50 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
fumigatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9191 >50 >50 10.54 <2 >50 - -  - - 
2380 - - 35.06 <2 >50 - -  - - 
9298 - - 29.18 <2 >50 - -  - - 
DC22 >50 >50 >50 <2 >50 - -  - - 
DC004 >50 >50 >50 <2 25.25 - -  - - 
DC038 - >50 >50 <2 - - -  - - 
DC299 - - 39.56 <2 >50 - -  - - 
2123 - - >50 <2 - - -  - - 
“-“ = Not Active 
Concentration:  50, 10, 2g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
Microorganism Drug Control IC50 (g/ml)
* MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.33 1.25 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.33 0.63 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.76 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 0.73 1.25 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.21 1.25 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.10 0.25 
Methicillin-resistant S. aureus ATCC 43300 (MRS) Ciprofloxacin 0.10 0.50 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.005 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.069 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.46 0.50 
 
 
 Subsequent assay data, reported in Table 6, shows several isolates with comparable 
activity against C. neoformans as the drug control Amphotericin B, which is used in its 
treatment.   Reported IC50 for two of the isolates, highlighted red in the table, are equal to or 
better than the control. 
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TABLE 6: ANTIMOCROBIAL ACTIVITY REPORT – TERTIARY (Data Set 2) 
 
*
IC50 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
fumigatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9191 >50 >50 23.56 0.91 >50 - -  - - 
2380 >50 - >50 0.67 >50 - -  - - 
9298 >50 - >50 0.61 >50 - -  - - 
DC22 >50 - 16.05 0.34 >50 - -  - - 
DC004 >50 - 10.10 0.60 16.63 - -  - - 
DC038 >50 12.59 18.66 0.43 >50 - -  - - 
DC299 >50 - >50 0.67 6.01 - -  - - 
2123 - - >50 0.22 >50 - -  - - 
“-“ = Not Active 
Concentration:  50, 10, 2, 0.4, 0.08, 0.016g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
 
Microorganism Drug Control IC50 (g/ml)
* MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.27 1.25 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.33 1.25 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.58 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.05 1.25 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.31 0.63 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.11 0.50 
Methicillin-resistant S. aureus ATCC 43300 (MRS) Ciprofloxacin 0.09 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.004 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.08 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.31 0.50 
 
 
 Antimicrobial data for another batch of samples is reported in Table 7.  As was the case 
with previous batches, the most activity was observed against C. neoformans, which a smaller 
proportion of the isolates showing activity against C. krusei, A. fumigatus, and E. coli.  Isolates 
producing >50% growth inhibition against any organism tested was again moved forward for 
secondary assay testing. 
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TABLE 7: ANTIMICROBIAL ACTIVITY REPORT – PRIMARY (Data Set 3) 
 % Growth Inhibition
1,2
 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
funmgatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
DC001 28 21 48 76 97 0 0 47 14 0 
6160 29 16 61 79 46* 0 1 58 11 21 
DC019 23 15 55 72 45 0 0 47 10 21 
5952 20 7 37 62 43 0 0 42 7 22 
DC347 22 18 50 64 20 0 11 60 4 0 
6300 19 11 51 74 46 0 0 43 11 20 
Concentration: 50g/ml 
1Samples showing % Growth Inhibition < 50 are considered inactive  
2Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 NOTE: * indicates a sample with disparate data 
 
 
 
TABLE 8: ANTIMOCROBIAL ACTIVITY REPORT – SECONDARY (Data Set 3) 
 
*
IC50 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
funmgatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
DC001 - - >50 43.12 6.53 - -  - - 
6160 - - 5.97 <2 - - -  - >50 
DC019 50.00 - 2.00 <2 >50 - -  - - 
5952 - - 2.00 <2 - - -  - - 
DC347 - >50 2.00 <2 - - 42.85  - - 
6300 - - 48.44 <2 - - -  - - 
“-“ = Not Active 
Concentration:  50, 10, 2g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
Microorganism Drug Control IC50 (g/ml)
* MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.45 1.25 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.38 1.25 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.71 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.06 1.25 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.29 0.63 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.12 0.50 
Methicillin-resistant S. aureus ATCC 43300 (MRS) Ciprofloxacin 0.13 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.006 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.092 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.30 0.50 
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Secondary assay data for this batch is reported in Table 8.  The IC50 value for the vast 
majority of the sample could not be attained against C. neoformans at the lowest test 
concentration (2g/ml); therefore 5 of the 6 fungal isolates were subjected to testing at lower 
concentrations.  The IC50 values reported for isolate DC001 against the other organisms tested 
were not shown to be significant. 
 
TABLE 9: ANTIMOCROBIAL ACTIVITY REPORT – TERTIARY (Data Set 3) 
 
*
IC50 
Anti-Fungal Anti-Bacterial 
Sample 
Name 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. 
neoformans 
A. 
funmgatus 
S. 
aures 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
6160 - - - 0.37 >50 - -  - - 
DC019 - - >50 0.25 >50 - -  - - 
5952 - - - 0.47 - - -  - >50 
DC347 - - >50 0.52 - - 28.63  - - 
6300 - - - 0.84 - - -  - - 
“-“ = Not Active 
Concentration:  50, 10, 2, 0.4, 0.08, 0.016 g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
Microorganism Drug Control IC50 (g/ml)
* MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.41 1.25 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.79 1.25 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.98 2.50 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.07 1.25 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.64 1.25 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.12 0.50 
Methicillin-resistant S. aureus ATCC 43300 (MRS) Ciprofloxacin 0.11 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.005 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.084 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.36 0.50 
 Four of the 5 isolated evaluated in Table 9 are shown to have been activity against C. 
neoformans than the drug control (all highlighted in red).   
 
 
 
 
 5.1b. Antimalarial Data 
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TABLE 10: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Primary Data Summary: 
Data Set 1 
 % Inhibition 
Sample Name P. falciparum  
(D6 Clone) 
P. falciparum 
(W2 Clone) 
Cytotoxicity 
(Vero) 
9188 77 NT NT 
DC657 18 NT NT 
DC018 0 NT NT 
9295 0 NT NT 
6249 82 NT NT 
DC509 84 NT NT 
9116 78 NT NT 
6063 82 NT NT 
6139 81 NT NT 
DC012 83 NT NT 
DC399 77 NT NT 
9054 86 NT NT 
DC376 82 NT NT 
9247 80 NT NT 
DC7 76 NT NT 
6262 83 NT NT 
NT = Not Tested 
Samples showing % Growth Inhibition < 50 are considered inactive at 15.9g/ml (extracts) or 1.59g/ml (pure)  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 
 In the primary malaria assay (shown in Table 10), the extracts are tested at a 
concentration of 15.9g/ml against only the chloroquine sensitive, D6 clone of P. falciparum.  
Those extracts showing 50% growth inhibition or more (shown in red) are confirmed in a 
secondary assay.  
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TABLE 11: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Secondary Data Summary: 
Data Set 1 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9188 <5288 >9.0 <5288 >9.0 NC 
6249 <5288 >9.0 <5288 >9.0 NC 
DC509 <5288 >9.0 <5288 >9.0 NC 
9116 <5288 >9.0 <5288 >9.0 NC 
6063 <5288 >9.0 <5288 >9.0 NC 
6139 NA - NA - NC 
DC012 7500 >6.3 8000 >6.0 NC 
DC399 NA - NA - NC 
9054 NA - NA - NC 
DC376 <5288 >9.0 <5288 >9.0 NC 
9247 <5288 >9.0 <5288 >9.0 NC 
DC7 <5288 >9.0 <5288 >9.0 NC 
6262 <5288 >9.0 <5288 >9.0 NC 
                 Concentrations:  47600, 15867, 5288 ng/ml 
NA = Inactive 
                               NC = No cytotoxicity 
Selectivity Index (S. I.) = IC50 (Vero Cells) / IC50 (P. 
falciparum) 
 
 
 
 
 
 
 Initially secondary assays are run at three test concentrations (47600, 15867, and 5288 
ng/ml) against both the chloroquine sensitive (D6) and chloroquine resistant (W2) clones of P. 
falciparum.  Cytotoxicity testing is also conducted in parallel on VERO cells (monkey kidney 
fibroblasts) by Neutral Red assay.  The IC50 values shown in Table 11 correspond to the 
concentration of extract causing 50% growth inhibition of the parasite.  Most of the extracts had 
IC50 values lower than the lowest test concentration (in red above) and were subjected to further 
testing. 
 
 
 
 
 
 
 D6 W2 
 CQ <26.4 125 
ART <26.4 <26.4 
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TABLE 12: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Tertiary Data Summary: 
Data Set 1 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9188 360 >132.2 520 >91.5 NC 
6249 <195 >244.1 <195 >244.1 NC 
DC509 <195 >244.1 <195 >244.1 NC 
9116 <195 >244.1 <195 >244.1 NC 
6063 <195 >244.1 <195 >244.1 NC 
DC376 <195 >244.1 <195 >244.1 NC 
9247 <195 >244.1 <195 >244.1 NC 
DC7 <195 >244.1 <195 >244.1 NC 
6262 <195 >244.1 <195 >244.1 NC 
      Concentrations:  47600, 15820, 5290, 1760, 560, 195 ng/ml 
         NA = Inactive 
  NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
                     IC50 (P. falciparum) 
 
 
 
 
 
 
TABLE 13: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Quaternary Data Summary: 
Data Set 1 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 24 >1983.3 27 >1763 NC 
DC509 26 >1830.8 32 >1487.5 NC 
9116 26 >1830.8 30 >1586.7 NC 
6063 25 >19.4 33 >1442.4 NC 
DC376 27 >1763 37 >1286.5 NC 
9247 40 >1190 62 >767.7 NC 
DC7 24 >1983.3 28 >1700 NC 
6262 28 >1700 22 >2163.6 NC 
           Concentrations:  4760, 1587, 529, 176, 56, 19.5 ng/ml 
         NA = Inactive 
  NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
            IC50 (P. falciparum) 
 
 
 
 
  
 D6 W2 
 CQ 12.5 125 
ART 4.7 8.5 
 D6 W2 
 CQ 16.0 110 
ART 5.0 9.5 
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Subsequent assays (data presented in Tables 12 and 13) showed IC50 values that were 
comparable to the control drugs chloroquine and artemisinin, the two primary agents used to 
treat malaria.  Additionally, none of the active extracts were found to be cytotoxic and all had 
good selectivity for the parasite over VERO cells. 
 For the batch of samples presented in Table 14, we again see very good antimalarial 
activity against the chloroquine sensitive D6 clone of P. falciparum, which all of our endophytes 
showing >90% growth inhibition of the parasite.  All isolates progressed to secondary assay 
testing. 
 
TABLE 14: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Primary Data Summary: 
Data Set 2 
 % Inhibition 
Sample Name P. falciparum  
(D6 Clone) 
P. falciparum 
(W2 Clone) 
Cytotoxicity 
(Vero) 
9191 92 NT NT 
2380 92 NT NT 
9288 94 NT NT 
DC22 91 NT NT 
DC004 96 NT NT 
DC038 91 NT NT 
DC299 90 NT NT 
2123 93 NT NT 
NT = Not Tested 
Samples showing % Growth Inhibition < 50 are considered inactive at 15.9g/ml (extracts) or 1.59g/ml (pure)  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 
 Tables 15 – 18 present data obtained from secondary, tertiary, quaternary, and quinary 
assays for this batch of isolates.  As with the previous batch of samples, these isolates were 
tested against both the D6 and W2 clones of P. falciparum.  The samples progressed to testing at 
lower and lower concentrations until the IC50 values were attained.  The IC50 values, reported in 
Table 18, show that isolated contained in this batch are just as effective against the chloroquine 
sensitive W2 clone of P. falciparum as it is against the chloroquine resistant strain (D6).   
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In addition to their lack of cytotoxicity, the isolates were shown to be more effective than 
chloroquine and just as effective as artemisinin against the strains tested.   
 
TABLE 15: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Secondary Data Summary: 
Data Set 2 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9191 <5288 >9.0 <5288 >9.0 NC 
2380 <5288 >9.0 <5288 >9.0 NC 
9288 <5288 >9.0 <5288 >9.0 NC 
DC22 <5288 >9.0 <5288 >9.0 NC 
DC004 <5288 >9.0 <5288 >9.0 NC 
DC038 <5288 >9.0 <5288 >9.0 NC 
DC299 <5288 >9.0 <5288 >9.0 NC 
2123 <5288 >9.0 <5288 >9.0 NC 
                 Concentrations:  47600, 15867, 5288 ng/ml 
NA = Inactive 
                           NC = No cytoxicity 
 Selectivity Index (S. I.) = IC50 (Vero Cells) / IC50 (P. 
falciparum) 
 
 
 
 
 
 
TABLE 16: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Tertiary Data Summary: 
Data Set 2 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9191 <195 >244.1 <195 >244.1 NC 
2380 <195 >244.1 <195 >244.1 NC 
9288 <195 >244.1 <195 >244.1 NC 
DC22 <195 >244.1 <195 >244.1 NC 
DC004 <195 >244.1 <195 >244.1 NC 
DC038 <195 >244.1 <195 >244.1 NC 
DC299 <195 >244.1 <195 >244.1 NC 
2123 <195 >244.1 <195 >244.1 NC 
      Concentrations:  47600, 15820, 5290, 1760, 560, 195 ng/ml 
         NA = Inactive 
  NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 D6 W2 
 CQ 15.0 115 
ART 4.9 3.7 
 D6 W2 
 CQ 16.0 110 
ART 4.4 4.6 
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TABLE 17: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Quaternary Data Summary: 
Data Set 2 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9191 <19.5 >2441 <19.5 >2441 NC 
2380 <19.5 >2441 <19.5 >2441 NC 
9288 <19.5 >2441 <19.5 >2441 NC 
DC22 <19.5 >2441 <19.5 >2441 NC 
DC004 <19.5 >2441 <19.5 >2441 NC 
DC038 <19.5 >2441 <19.5 >2441 NC 
DC299 <19.5 >2441 <19.5 >2441 NC 
2123 <19.5 >2441 <19.5 >2441 NC 
           Concentrations:  4760, 1587, 5290 176, 56, 19.5 ng/ml 
NA = Inactive 
  NC = No cytoxicity 
Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 
 
 
 
TABLE 18: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Quinary Data Summary: 
Data Set 2 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9191 11 >4327.3 14 >3400 NC 
2380 9 >5288.9 12 >3966.7 NC 
9288 10 >4760 17 >2800 NC 
DC22 7 >6800 8.8 >5409.1 NC 
DC004 8.4 >5666.7 9.8 >4857.1 NC 
DC038 7.8 >6102.6 11 >4327.3 NC 
DC299 8.7 >5471.3 10 >4760 NC 
2123 8.3 >5734.9 8.7 >5471.3 NC 
           Concentrations:  476, 159, 53 18, 6, 1.95 ng/ml 
NA = Inactive 
  NC = No cytoxicity 
Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 
 
 D6 W2 
 CQ 16.0 110 
ART 4.4 4.6 
 D6 W2 
 CQ 12.0 125 
ART 5.0 4.8 
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 Similar data was returned for the batch of samples presented in Table 19; all of the fungal 
extracts were found to have antimalarial activity in the primary assay.  They were therefore 
subjected to secondary assay screening, the results for which, is presented in Tables 20 – 23. 
  
TABLE 19: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Primary Data Summary: 
Data Set 3 
 % Inhibition 
Sample Name P. falciparum  
(D6 Clone) 
P. falciparum 
(W2 Clone) 
Cytotoxicity 
(Vero) 
DC001 95 NT NT 
6160 99 NT NT 
DC019 94 NT NT 
5952 94 NT NT 
DC347 94 NT NT 
6300 95 NT NT 
NT = Not Tested 
Samples showing % Growth Inhibition < 50 are considered inactive at 15.9g/ml (extracts) or 1.59g/ml (pure)  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 
 
TABLE 20: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Secondary Data Summary: 
Data Set 3 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
DC001 <5288 >9.0 <5288 >9.0 NC 
6160 <5288 >9.0 <5288 >9.0 NC 
DC019 <5288 >9.0 <5288 >9.0 NC 
5952 <5288 >9.0 <5288 >9.0 NC 
DC347 <5288 >9.0 <5288 >9.0 NC 
6300 <5288 >9.0 <5288 >9.0 NC 
                 Concentrations:  47600, 15867, 5288 ng/ml 
NA = Inactive 
                           NC = No cytoxicity 
 Selectivity Index (S. I.) = IC50 (Vero Cells) / IC50 (P. 
falciparum) 
 
 
 
 
 
 
 
 
 
 D6 W2 
 CQ 15.0 115 
ART 4.9 3.7 
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TABLE 21: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Tertiary Data Summary: 
Data Set 3 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
DC001 <195 >244.1 <195 >244.1 NC 
6160 <195 >244.1 <195 >244.1 NC 
DC019 <195 >244.1 <195 >244.1 NC 
5952 <195 >244.1 <195 >244.1 NC 
DC347 <195 >244.1 <195 >244.1 NC 
6300 <195 >244.1 <195 >244.1 NC 
      Concentrations:  47600, 15820, 5290, 1760, 560, 195 ng/ml 
NA = Inactive 
  NC = No cytoxicity 
Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 
 
 
TABLE 22: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Quaternary Data Summary: 
Data Set 3 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
DC001 <19.5 >2441 <19.5 >2441 NC 
6160 <19.5 >2441 <19.5 >2441 NC 
DC019 <19.5 >2441 <19.5 >2441 NC 
5952 <19.5 >2441 <19.5 >2441 NC 
DC347 <19.5 >2441 <19.5 >2441 NC 
6300 <19.5 >2441 <19.5 >2441 NC 
           Concentrations:  4760, 1587, 5290 176, 56, 19.5 ng/ml 
NA = Inactive 
  NC = No cytoxicity 
Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 
 
 The IC50 values reported in Table 23 indicates the isolates are just as effective against the 
W2 clone as it is against the D6 clone.  Again we see that activity comparable to that of 
artemisinin, which is currently the drug of choice for the treatment of malaria. 
 
 D6 W2 
 CQ 16.0 110 
ART 4.4 4.6 
 D6 W2 
 CQ 16.0 110 
ART 4.4 4.6 
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TABLE 23: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Quinary Data Summary: 
Data Set 3 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
DC001 9.7 >4907 13 >3611.5 NC 
6160 9 >5288.9 12 >3966.7 NC 
DC019 11 >4327 12 >3966.7 NC 
5952 7.5 >6346.7 10 >4760 NC 
DC347 8.6 >5534.9 10 >4760 NC 
6300 8.7 >5471.3 10 >4760 NC 
           Concentrations:  476, 159, 53 18, 6, 1.95 ng/ml 
               NA = Inactive 
              NC = No cytoxicity 
               Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 
 
 
5.1c. Leishmania Data 
 
 Primary screening of the extracts in the anti-leishmania assay was done using a culture of 
L. donovani promastigotes.  In this assay, again, those extracts showing 50% growth inhibition or 
better are comfirmed in a secondary assay.  Of the extracts submitted, only one showed activity 
(Table 24).  With over 99% growth inhibition, DC012 was subjected to secondary assay testing.  
The assay was run at three concentrations (40, 8, and 1.6g/ml).  The reported IC50 and IC90 
values represent the sample concentrations that kill 50 and 90% of the cells, respectively (Table 
25).  The observed values are comparable to those for the drug control Pentamidine and present a 
possible drug lead for the treatment of leishmania. 
 
 
 
 
 
 
 
 
 D6 W2 
 CQ 12.0 125 
ART 5.0 4.8 
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TABLE 24: ANTIPROTOZOAL SCREENING ASSAYS 
Leishmania Primary Data Summary: Data Set 1 
Sample Name % Inhibition 
9188 3.05 
DC657 5.45 
DC018 4.07 
9295 7.10 
6249 39.85 
DC509 31.46 
9116 37.64 
6063 39.33 
6139 1.44 
DC012 99.53 
DC399 4.58 
9054 8.11 
DC376 25.64 
9247 8.64 
DC7 29.44 
6262 38.49 
Concentration: 80g/ml 
Samples showing % Growth Inhibition < 50 are considered inactive  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 % Inh 
Amph B 100.0 
 
 
 
TABLE 25: ANTIPROTOZOAL SCREENING ASSAYS – Leishmania Secondary Data 
Summary: Data Set 1 
Sample Name IC50 (g/ml) IC90 (g/ml) 
DC012 5 24 
 
        Concentrations: 40, 8, 1.6 g/ml 
 
 
 
 IC50 (g/ml) IC90 (g/ml) 
Pentamidine 1.2 5 
Amph B 0.2 0.4 
IC50 and IC90 are the sample concentrations that kill 50% and 90% cells compared to the solvent controls 
 
Submitted samples from other batches and there returned data are presented in Tables 26 
– 29.  While many of them showed some promise in the primary assay screenings; none were 
found to be active in the secondary leishmania assay. 
54 
 
TABLE 26: ANTIPROTOZOAL SCREENING ASSAYS 
Leishmania Primary Data Summary: Data Set 2 
Sample Name % Inhibition 
9191 69.19 
2380 76.23 
9298 62.91 
DC22 68.40 
DC004 72.01 
DC038 66.40 
DC299 61.47 
2123 77.94 
Concentration: 80g/ml 
Samples showing % Growth Inhibition < 50 are considered inactive  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 % Inh 
Amph B 100.0 
 
 
TABLE 27: ANTIPROTOZOAL SCREENING ASSAYS – Leishmania Secondary Data 
Summary: Data Set 2 
Sample Name IC50 (g/ml) IC90 (g/ml) 
9191 NA NA 
2380 NA NA 
9298 NA NA 
DC22 NA NA 
DC004 NA NA 
DC038 NA NA 
DC299 NA NA 
2123 NA NA 
   
 
        Concentrations: 40, 8, 1.6 g/ml 
 
 
 
 IC50 (g/ml) IC90 (g/ml) 
Pentamidine 1.1 4 
Amph B 0.14 0.3 
IC50 and IC90 are the sample concentrations that kill 50% and 90% cells compared to the solvent controls 
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TABLE 28: ANTIPROTOZOAL SCREENING ASSAYS 
Leishmania Primary Data Summary: Data Set 3 
Sample Name % Inhibition 
DC001 47.30 
6160 48.72 
DC019 54.04 
5952 53.57 
DC347 79.22 
6300 50.17 
Concentration: 80g/ml 
Samples showing % Growth Inhibition < 50 are considered inactive  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 % Inh 
Amph B 100.0 
 
 
 
TABLE 29: ANTIPROTOZOAL SCREENING ASSAYS – Leishmania Secondary Data 
Summary: Data Set 3 
Sample Name IC50 (g/ml) IC90 (g/ml) 
DC019 >40 >40 
5952 >40 >40 
DC347 >40 >40 
6300 >40 >40 
   
 
        Concentrations: 40, 8, 1.6 g/ml 
 
 
 
 IC50 (g/ml) IC90 (g/ml) 
Pentamidine 1 2 
Amph B 0.19 0.32 
IC50 and IC90 are the sample concentrations that kill 50% and 90% cells compared to the solvent controls 
 
Using our collection of various endophytic fungi, we found that many of their extracts 
possessed very good antimicrobial and/or antimalarial activities.  As many fungal organisms are 
known to produce antibiotics, the antimicrobial results were not too surprising.  
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However, with little known about the antiprotozoal properties associated with fungal endophytes, 
this avenue was worth pursuing.  We therefore sought confirmation that the extracts of our 
fungal endophytes were indeed active against malaria. 
 
5.2 Confirmation of Preliminary Malaria Data 
Some of the isolates found to be active against in the preliminary assays were re-grown in 
50ml of PDB and extracted in EtOAc (v/v) as previously described.  These isolates, listed in 
Tables 30 and 31, were resubmitted to the malaria assay for confirmation of their activity. 
 
TABLE 30: ANTIPROTOZOAL ASSAY – Malaria Confirmation Data Summary 1 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9116 28 >170 20 >238 NC 
6063 63 >75.6 42 >113.3 NC 
DC376 28 >170 22 >216.4 NC 
6262 28 >170 26 >183.1 NC 
           Concentrations:  4760, 1587, 5290 176, 56, 19.5 ng/ml 
         NA = Inactive 
     NC = No cytotoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
             IC50 (P. falciparum) 
 
 
TABLE 31: ANTIPROTOZOAL ASSAY – Malaria Confirmation Data Summary 2 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 3.4 >1400 5 >952 NC 
DC509 8 >595 10 >476 NC 
9247 8.2 >580 9 >528.9 NC 
DC7 7.3 >652.1 9.5 >501.1 NC 
              Concentrations:  476, 159, 53, 18, 6, 1.95 ng/ml 
         NA = Inactive 
  NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
             IC50 (P. falciparum) 
 
 
 
 D6 W2 
 CQ 13.5 115 
ART 6.0 4.1 
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5.3 Bio-assay Guided Fractionation of 6249 
After data confirming the activity of our extracts was obtained, we selected one sample, 
6249, from which we would attempt to isolate the active constituent(s) of the extract.  To do this, 
we began growing the sample on a larger scale; 6-500ml PDB cultures were grown to obtain 
more extract.  The samples were again incubated, with shaking, at 30°C for 14 days, after which, 
they were extracted (v/v) with EtOAc in the manner previously stated, 390mg of extract was 
obtained.  Once extracted, we began the work of fractionating the extract in an effort to identify 
the source of its antimalarial activity. 
  
5.3a. Fractionation Attempt 1 – RP-chromatography 
 We first attempted reversed-phased fractionation using a pre-packed, Alltech Extract-
Clean C18 SPE (Solid Phase Extraction) Column (1.0g bed weight, 8.0ml tube size), which was 
equilibrated with water.  Using 10mg of our 6249 extract, we eluted our sample (with a syringe) 
using a gradient going from 100% water to 100% methanol (increments of 10) with a 30ml 
elution volume for each fraction.  Only the 9:1; 8:2; 7:3 MeOH:H2O fractions contained enough 
material for assay submission (1mg minimum); these fractions were submitted for malaria assay 
testing.  The assay data for these fractions is presented in Table 32.  None of the fractions were 
found to be active.  Although IC50 values of 2300 and 1700ng/ml were reported for the 9:1 
fraction against the D6 and W2 clones of P. falciparum respectively, this was much larger than 
that reported for the crude extract against either strain. 
 
 
 
 
58 
 
TABLE 32: ANTIPROTOZOAL SCREENING ASSAYS – Malaria RP Fraction Data Summary 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 9:1 
MeOH/H2O 
2300 >2.1 1700 >2.8 NC 
6249 8:2 
MeOH/H2O 
NA - NA - NC 
6249 7:3 
MeOH/H2O 
NA - NA - NC 
                 Concentrations:  4760, 1587, 528.8 ng/ml 
         NA = Inactive 
  NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
            IC50 (P. falciparum) 
 
 
 
 
 
5.3b. Fractionation Attempt 2 – VLC 
As our previous attempt using only MeOH and water as eluting solvents had failed, our 
second attempt at fractionation included the use of several eluting solvents, namely hexanes 
(Hex), EtOAc, MeOH, and water, in various combinations.  One of the problems noted from the 
first attempt was that we were limited in the amount of material we could load onto the 
prepacked column, which resulted in us not having enough material in some fractions for assay 
submission.  For this reason, we tried vacuum liquid chromatography (VLC) using the setup 
depicted in Figure 12 below.  As it appeared, from the assay data received, that our active 
compound stuck to the column in our previous attempt, we decided to try silica [Merck Silica 
Gel 60 (70-230 mesh; Sigma-Aldrich)] as our stationery phase in this attempt.  One hundred 
milligrams of crude extract (6249), mixed in a 1:2 ration with celite; the sample was eluted in a 
normal phase manner using 100% Hex; 100% EtOAc; 50:50 EtOAc:MeOH; 100% MeOH; and 
50:50 MeOH:H2O (200ml per fraction). 
 
 D6 W2 
 CQ 15.0 135 
ART 5.5 4.5 
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    Funnel 
      
           
 
   500ml Flask 
 
Figure 13: VLC setup. 
 
All fractions, with the exception of the 100% Hex fraction, were submitted for antimalarial 
testing.  The 100 Hex fraction was not tested because <1mg of material was contained in the 
fraction, which was not enough to submit for assay testing.  Table 33 contains the data returned 
for these fractions. 
 
TABLE 33: ANTIPROTOZOAL SCREENING ASSAYS – Malaria VLC Data Summary 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 100 EtOAc 
 
<5288 >9.0 <5288 >9.0 NC 
6249 50:50 
EtOAC/MeOH 
<5288 >9.0 <5288 >9.0 NC 
6249 100 MeOH 
 
<5288 >9.0 <5288 >9.0 NC 
6249 50:50 
MeOH/H2O 
47600 >1.0 3800 >1.3 NC 
                     Concentrations:  47600, 15867, 5288 ng/ml 
   NC = No cytoxicity 
 Selectivity Index (S. I.) = IC50 (Vero Cells) / 
    IC50 (P. falciparum) 
 
 
 
 D6 W2 
 CQ 17.0 130 
ART 4.5 5.5 
Cotton 
Silica 
Filter paper 
Sample mixed with Celite 1:2 
Connected to vacuum pump 
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The 50:50 MeOH:H2O fraction was clearly shown to be inactive against both P. 
falciparum clones tested, relative to the IC50 returned for the crude extract in preliminary testing.  
While there appeared to be potential activity in each of the other fractions as their IC50 values are 
reported to be less than the lowest concentration tested (5288ng/ml), these fraction were also 
assumed to be inactive in subsequent assays as not further data was returned. 
 
5.3c. Fractionation Attempt 3 – HPLC 
While the data from the second fractionation attempt was still not what we hoped it 
would be, the data from those fractions was an improvement over our first attempt.  In our next 
attempt we decided to stick with normal phase, combining our SPE technique with HPLC.  We 
used SPE columns to clean up our extract, prior to loading it onto the HPLC.  As it appeared our 
active metabolite had again stuck to the column, we chose to use a new stationary phase; a 
prepacked, Alltech Extract Clean amino (NH2) column (1.0g/8.0ml).   
Using a solid phase extraction manifold chamber, the column, under pressure, was 
washed twice with methanol (15ml) followed by a chloroform (CHCl3) wash; the analyte 50mg 
was then loaded onto the column.  The column was first eluted with water (6.0ml) twice, then 
three times with 6.0ml CHCl3 followed by MeOH three times as well.  The CHCl3 and MeOH 
fractions were combined and evaporated to dryness and weighed.  The combined fraction was re-
dissolved in ~250l of CHCl3 and run on HPLC [preparative HPLC; Waters Delta Prep 4000 
with Waters 2487 dual  absorbance and Polymer Laboratories Evaporative Light Scattering 
(PL-ELS 1000) detectors attached].  The sample was directly injected and run using a 
Phenomenex Phensophere 10u, NH2 80A, 250 x 10mm column on a gradient from 100% CHCl3 
to 100% MeOH at a flow rate of 6.0ml/min over a 30 min time span. 
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    Fraction 1   
             Fraction 2 
 
 
 
 
 
 
 
Figure 14: ELS and UV traces from HPLC run of 6249. 
 
Two fractions were collected based on ELS detection (Fig. 14): fraction 1 (1mg) at 
~2min (99:1 CHCl3:MeOH) and fraction 2 (1mg) at ~15min (50:50 CHCl3:MeOH).  This run 
was repeated under the same conditions and produced the same two peaks (Fig. 15).  Fractions 1 
and 2 from the second run were combined with fractions 1 and 2 from the first run respectively.  
Both fractions were submitted for antimalarial assay testing. 
Assay results for the HPLC fractions, shown in Table 34, reports our antimalarial activity 
to be contained in fraction 1.  The IC50 value is reported as <528.8ng/ml which is the lowest test 
concentration for column fractions; only pure fractions are tested at lower concentrations. 
As both fractions collected from these initial runs appeared to be mixtures of two or more 
compounds with retention times very close to that of our active compound, we began to modify 
our HPLC conditions and solvents in an effort to improve separation. 
ELS trace 
UV trace 
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          ELS trace 
      Fraction 1       Fraction 2  
 
 
 
 
         
UV trace 
 
 
 
 
 
 
 
Figure 15: Repeat of initial HPLC run. 
 
 
 
TABLE 34: ANTIPROTOZOAL SCREENING ASSAYS – Malaria HPLC Data Summary 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 99:1 
CHCl3/MeOH 
<528.8 >9.0 <528.8 >9.0 NC 
6249 50:50 
CHCl3/MeOH 
NA - NA - NC 
                 Concentrations:  4760, 1587, 528.8 ng/ml 
         NA = Inactive 
  NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
     IC50 (P. falciparum) 
 
 
 
 
 
 
A new batch of 6249 was grown and extracted using aforementioned procedures.  
 D6 W2 
 CQ 16.5 150 
ART 6.5 6.5 
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 Before modifying any of our conditions, we ran the extract using our initial HPLC conditions 
(gradient: 100 CHCl3 to 100 MeOH; flow rate: 6ml/min; run time: 30min).  The chromatogram 
for this run is shown in Figure 16. 
 
 
6249 (10mg) 
Run on 10mm NH2 column (no guard) 
        Fraction 1  Run time = 30 Mins 
Solvent run = from 100 CHCl3 to 100 MeOH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: HPLC chromatogram. 
 
 
As was the case in the initial run, multiple peaks again co-eluted at ~2min.  Based on 
previously reported assay data, this fraction was assumed to contain our active compound.  After 
solvent evaporation, the fraction weighed ~1mg.  Noticeably absent from this chromatogram is 
the peak that appeared at ~15min (50:50 CHCl3:MeOH) in our initial run.  This is due to the fact 
that the trace depicted here represents a rerun of 3 fractions (from sample 6249) that eluted at 
retention times within 0.01seconds of each other.  As these fractions were difficult to collect 
individually without losing any material, they were collected together, dried down, and rerun on 
the machine.   
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The fraction collected at 15min in the early run was not rerun a second time as assay data from 
our first run (Table 34) had shown it to be inactive.  Fraction 1 (~1mg), pictured in Figure 16, 
was dissolved in d-chloroform (CDCl3) and analyzed via 
1
H-NMR (proton Nuclear Magnetic 
Resonance).  Although the fraction was not pure, as can be seen from multiple peaks observed on 
the HPLC chromatogram (Figure 16), we figured an NMR spectrum would provide some insight 
as to the class of compounds with which we were working.  This 
1
H-NMR spectrum is presented 
in Figure 17. 
 
 
Figure 17: 
1
H-NMR of active fraction isolated from 6249 by HPLC/ELS fractionation. 
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We concluded, based on hydrocarbon proton signals observed in the aliphatic region (=0.5-1.5 
ppm) of the spectrum, that we might be working with a terpenoid-type compound.  The 
downfield signals around =3-4 ppm indicated the possibility of an electronegative atom 
deshielding adjacent protons while the signals between =5-6 ppm suggests the presence of 
unsaturation in one or more of the C-C bonds.  However, without a pure compound, it was 
difficult to draw any definitive conclusions. 
 
 5.3d. Attempts to improve HPLC/ELS separation 
 Previous HPLC runs netted fractions contain ~1mg of compound.  In an effort to improve 
separation, we changed the solvents and solvent gradient.  To obtain more material for further 
study, we used more sample; in previous runs, 50mg of crude extract was loaded onto pre-
packed cartridges for pre-filtering and ~10mg was obtained for HPLC injection. For the run 
described below, 150mg of crude extract (6249) was used.  Our pre-packed columns could only 
hold up to 100mg of sample; two columns were used, loading 75mg of extract onto each.   As 
was the case in previous runs, the pre-packed columns were washed first with MeOH (2X) 
followed by CHCl3 (2X) prior to loading the sample.  The sample was again eluted with H2O 
(2X) followed sequentially by CHCl3 (3X) and MeOH (3X); the eluting volume was 6.0ml for 
each elution.  The MeOH and CHCl3 fractions were combined and dried; 25mg was obtained for 
HPLC.  Of the 25mg obtained after pre-filtering, 13mg was re-dissolved in 50:50 hex:DCM 
(dichloromethane) and directly injected into the HPLC.  The sample was again run on a 10mm x 
250mm NH2 column (Phenomenex) at a flow rate of 6ml/min.  The gradient started with a ratio 
of 80:20 hex:DCM and went to 100% DCM over 30 minutes.  
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The gradient then immediately from 100% DCM to 100% MeOH over 15 minutes where it held, 
running isocratic in 100% MeOH for 10 minutes.  After 10 minutes running isocratic, the 
machine went back to its starting conditions (80:20 hex:DCM) over 5 minutes and held for 10 
minutes.  The total run time was 70 minutes.  Hexanes was used as an eluting solvent here 
because we sought to improve the separation between our active compound and other lipids 
present in the extract.  In addition, a delay in the retention time of our compound was expected as 
is typically the case when employing more non-polar solvents.  A total of 8 fractions were 
collected from this run; the HPLC/ELS chromatogram is shown in Figure 18. 
 
 
 
 
Solvent gradient: 
80 Hex : 20 DCM at 0 min 
0 Hex : 100 DCM at 30 min 
          100 DCM : 100 MeOH at 45 min 
          100 MeOH at 55 min 
          80 Hex : 20 DCM at 60 min 
          80 Hex : 20 DCM at 70 min 
 
 
 
 
Figure 18: ELS trace obtained after modifying conditions. 
 
Fraction 1 was collected at ~2min (~78:22 hex: DCM) and contain 2 closely eluting 
peaks; fraction 2, eluting very close to fraction 1 was collected at approximately 3.5mins in 
~75:25 hex:DCM.  Fractions 3 (60 hex:40 DCM), 4 (50 hex:50 DCM), and 5 (23 hex:77 DCM) 
were collected at 8.75, 12, and 21.5mins respectively.  Fraction 6 was collected at the start of the 
DCM to MeOH gradient; it was collected in 99:1 DCM:MeOH at round 30.5mins.   
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Fraction 7 (35mins) was collected in 64:36 DCM:MeOH and fraction 8 (42mins) was collected 
in 16:84 DCM:MeOH.  
1
H-NMR was taken of fraction 1 (4mg), which was believed to contain 
my active compound (Figure 19).  Fraction 1, along with fractions 2 and 7 submitted for the 
antimalarial assay.   
 
 
Figure 19: 
1
H-NMR of fraction 1 isolated from 6249 by modified HPLC/ELS fractionation. 
 
 
Though our goal with the solvent and gradient changes was to improve separation and 
delay the retention times, our compound still eluted at ~2mins as can be seen in both the ELS 
trace (Fig. 18) and the 
1
H-NMR spectra (Figs. 19).   
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Filtered crude 
extract of 6249  
(12mg) 
100 Hex (2ml) 
2mg 
obtained 
80 Hex: 20 DCM 
(2ml) 
5mg 
obtained 
50 Hex: 50 DCM 
(2ml) 
1mg 
obtained 
100 DCM (2ml) 
2mg 
obtained 
50 DCM: 50 
MeOH (2ml) 
1mg 
obtained 
Therefore, rather than inject the 12mg of 6249 remaining from our pre-filtered extract into the 
HPLC, we chose to wash the sample using the solvent scheme that follows (Scheme 1).  Each 
solvent was individually added, shaken, and decanted; each solvent fraction was dried down and 
weighed.  These fractions were all submitted to the antimalarial assay.  The 8:2 hex: DCM 
fraction generated 5mg of material; approximately 2mg was submitted for assay while the 
remaining material was evaluated further.   
 
 
 
 
 
 
 
 
 
Scheme 1: Elution scheme for filtered extract 6249. 
 
The ~3mg of the 8:2 Hex: DCM fraction remaining after assay submission was directly injected 
into the HPLC using a 10mm x 250mm NH2 column with modified conditions applied to the run.  
A flow rate of 10ml/min; the solvent started with 100% hexanes running isocratic for 10 minutes 
then going to 80:20 hex: DCM over 50 minutes.  The gradient then went immediately from 80:20 
to 50:50 hex: DCM over 20 minutes and then to 100 DCM over another 20 minutes.  The 
machine was programmed to run isocratic with 100 % DCM for 5 minutes and then go to 100% 
MeOH over 5 minutes where it would again run isocratic for 10 minutes.  
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The total runtime was 120 minutes.  However, at ~90 minutes into the run, a manual change 
from the gradient run to an isocratic run at 50:50 MeOH: DCM was made; the system ran this 
way for 30 minutes. 
A total of 7 fractions were collected; however, as previous antimalarial assay data 
indicated that the fraction eluting in 50:50 CH3Cl: MeOH was not active (Table 34), we expected 
the same behavior in DCM as the two solvents share very similar chemical properties.  
We therefore did not work further with those fractions (5 – 7) here.  Fractions 1 – 4 were run on 
the 
1
H-NMR; fraction 3 looked to be my active compound (Figure 21).  All 4 fractions were 
submitted to the antimalarial assay. 
 
 
 
 
 
 
Figure 20: ELS trace of 80:20 hex: DCM fraction 
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Figure 21: 
1
H-NMR of fraction 3 isolated from HPLC/ELS fractionation of 80 Hex: 20 DCM fraction. 
 
 
Antimalarial assay data for the previous three fractionation/separation attempts 
(represented in Figs. 18 and 20; Scheme 1) was returned together as one dataset and is presented 
in Table 35.  Data reported for the first three samples in the list (Table 35) represents fractions 1, 
2, and 7 from the HPLC run of the 6249 extract detailed in Figure 18.  The data shows that both 
of the early eluting fractions were active, with fraction 1 eluting at ~2mins (78:22 hex:DCM) and 
fraction 2 eluting at ~3.5mins (75:25 hex:DCM).  In addition fraction 7, which eluted the column 
at ~35mins (64:36 DCM:MeOH) was also shown to have activity.  None of the fractions were 
found to be cytotoxic in the cytotoxicity assay. 
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TABLE 35: ANTIPROTOZOAL ASSAY – Malaria Modified HPLC and Column Fraction Data 
Summary 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 HPLC Frac 
1 (5/19) 
<528.8 >9.0 <528.8 >9.0 NC 
6249 HPLC Frac 
2 (5/19) 
<528.8 >9.0 <528.8 >9.0 NC 
6249 HPLC Frac 
7 (5/19) 
<528.8 >9.0 <528.8 >9.0 NC 
6249 100 Hex <528.8 >9.0 <528.8 >9.0 NC 
6249 80 Hex: 20 
DCM 
<528.8 >9.0 <528.8 >9.0 NC 
6249 50 Hex: 50 
DCM 
<528.8 >9.0 <528.8 >9.0 NC 
6249 100 DCM 600 >7.9 <528.8 >9.0 NC 
6249 50 DCM: 
50 MeOH 
<528.8 >9.0 <528.8 >9.0 NC 
6249 HPLC Frac 
1 (5/27) 
<528.8 >9.0 <528.8 >9.0 NC 
6249 HPLC Frac 
2 (5/27) 
4760 >1.0 NA - NC 
6249 HPLC Frac 
3 (5/27) 
<528.8 >9.0 <528.8 >9.0 NC 
6249 HPLC Frac 
4 (5/27) 
800 >6.0 700 >6.8 NC 
                 Concentrations:  4760, 1587, 528.8 ng/ml 
         NA = Not Activeb 
         NC = No cytoxicity 
         Selectivity Index (S. I.) = IC50 (Vero Cells) / 
   IC50 (P. falciparum) 
 
 
 
 
 The next five samples (in Table 35) correspond to the fractions obtained from “washing” 
the pre-filtered 6249 crude extract with various solvents and/or solvent ratios as outlined in 
Scheme 1.  With the exception of the 100 DCM fraction, all reported IC50 values less than 
528.8ng/ml, which is the lowest test concentration for column fractions.  Again, none of the 
fractions are reported to be cyctotoxic. 
 D6 W2 
 CQ 15.0 135 
ART 4.2 4.4 
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 The final four samples in the table (Table 35) represent data for HPLC fractions 1 – 4 
obtained from an HPLC run of the 80:20 hex: DCM fraction of 6249 pre-filtered extract (Fig. 
20).  All four fractions eluted in 100% hex and were collected within the first 6 minutes of the 
run.  Only fractions 1 and 3 were found to be active against malaria; data from the cytotoxicity 
assay reports none of these fractions are cytotoxic. 
 Again we can see from the biological data that the activity of our compound is retained.  
Additionally, the NMR data, when compared to our first/reference 
1
H-NMR spectrum shows 
consistent chemical shifts amongst the batches (Figs 17, 19, and 21). (*NOTE: NMR data is 
shown only for those fractions for which enough material was isolated to produce reliable data). 
 As we were able to reproduce the activity and NMR data between batches, we wanted to 
run more analytical tests to possibly obtain a mass for our compound.  We also wanted to 
develop an HPLC method in which we would be able to isolate more material in our active 
fraction(s); up to this point, we would only obtain a very small amount of material (< 2mg per 
fraction), most of which was needed for assay testing.  This limited the analytical tests we could 
run.  To obtain fractions for mass spectral analyses, we took 43mg of the 6249 crude extract and 
pre-filtered it on a pre-packed NH2 cartridge (Alltech; 1.0g/8.0ml) using water, CHCl3, and 
MeOH according to our established methodology.  The CHCl3 and MeOH fractions were again 
combined, dried, and re-dissolved in 100% hexanes (200l).  The sample was directly injected 
into the HPLC; it was run on a 10mm x 250mm amino column (Phenomenex) at a flow of 
10ml/min.  The solvent gradient, exacted the same as that represented in Figure 20, started with a 
10 minute isocratic run of 100% hexanes.  Over a 50 minute span, the solvent then went from 
100% hexanes to 80:20 hex: DCM, after which, it went to 50:50 hex: DCM over 20 minutes.   
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The run again went immediately from 50:50 hex: DCM to 100 DCM over 20 minutes where it 
was set to run isocratic for 5 minutes before going to 100% MeOH over 5 minutes.  The machine 
was programmed to run in 100% MeOH for 10 minutes; the total run time was again 120 
minutes.  The chromatograph is shown in Figure 22. 
 
 
 
 
 
 
Figure 22: HPLC/ELS trace of 6249 crude extract. 
 
Again we see what is believed to be our compound eluting within the first 5 minutes of the run.  
As was the case in the previous run, a manual change from the gradient run to an isocratic run 
was made; the changed occurred at ~65 minutes where the system ran in 100% MeOH. A total of 
3 fractions were collected, with fraction 1 at ~2 minutes and fraction 2 at ~4 minutes both eluting 
in 100% hexanes while fraction 3 was collected at ~67 minutes, after the manual change to 100% 
MeOH was made. 
 Fraction 1 and 2 from this HPLC run were dried and re-dissolved in MeOH for mass 
spectrum analysis.  The fractions were analyzed on an Agilent HP1100 with Bruker micro-TOF 
using a Gemini-NX C18 column (6mm x 150mm, 5, 110A) with a 0.6 ml/min flow rate.  The 
solvent gradient went from 80:20 water: MeOH to 100% MeOH over 20 minutes.   
74 
 
NMR data from previous runs had shown our terpenoid-like compound to be contained in 
fractions eluting at ~3.5 – 4 minutes, so we assumed fraction 2 would contain our compound.  
The LCMS data for fraction 2 is shown in Figure 23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: LCMS data for 6249 fraction 2. 
 
At this point we were not sure about the mass of our compound as we believed it to be poorly 
ionized here.  While subsequent data thoroughly explains this mass spectrum, we found this to be 
inconclusive as we were not even sure of our carbon count.  Because only very small amounts of 
material had been isolated in each of our fractions, we had been unable to obtain a 
13
C-NMR 
spectrum.  Needless to say, we needed more data to elucidate the structure of our compound. 
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 More attempts, focusing solely in improving separation, were made by altering our run 
conditions.  For these attempts we grew and extracted 50ml 6249 cultures as previously 
described.  In one attempt, the sample (19mg) was injected and run on a 10mm x 150mm NH2 
column (Phenomenex) at a flow of 6.0ml/min.  The system ran in 100% hexanes for 2 minutes, 
after which it went from 100% hex to 100% DCM over 20 minutes.  This was followed 
immediately by a linear gradient from 100% DCM to 100% MeOH over 20 minutes.  The system 
ran isocratic in 100% MeOH for 5 minutes; the total run time was 47 minutes.  A total of 4 peaks 
were collected on the ELS detector, all within the first five minutes.  As can be seen in Figure 24, 
the peaks were still not very well resolved using these conditions. 
 
 
 
 
 
Figure 24: ELS chromatogram of sample 6249 which shows a lack of separation. 
 
 In another injection of pre-filtered 6249 extract (10mg), using the same NH2 column and 
flow rate (6.oml/min), the sample was run isocratic in 100% hexanes just as in previous runs.  
They system them began a gradient going from 100% hexanes to 100% DCM over 60 minutes, 
slowing the gradient from previous runs.  The solvent then went quickly to 100% MeOH (over 5 
minutes) where it ran isocratic; the total run time for this injection was 70 minutes.  The ELS 
chromatogram is presented in Figure 25. 
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Figure 25: ELS chromatogram of another injection of 6249.  Top: An ELS trace of the entire run, 
showing four fractions.  Bottom:  A magnified version of the top chromatogram showing two closely 
eluting peaks at ~6 minutes. 
 
Four peaks were observed on the ELS detector (Figure 25), the first eluting at ~2.5min.  
Fractions 2 and 3 eluted very close together with retention times of ~6mins and 6.5mins 
respectively.  Each of the first 3 peaks detected by ELS again eluted with 100% hexanes.  A 
fourth ELS peak was observed at ~65mins as the system went to 100 MeOH; however, this 
fraction was disregarded as the 100% MeOH run was added to clean the column.  While 
separation between fractions 1 and 2 improved, fractions 2 and 3 retention times were less than a 
second apart.  After several more attempts that failed to yield neither better separation nor more 
of material to work with it our fractions, we opted to move away from HPLC and pursue other 
separation measures. 
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5.3e. Scaling up to obtain more of our active compound 
 After numerous injections, we were still not collecting enough material in our fractions to 
run a 
13
C-NMR, which would greatly aid our structure elucidation efforts.  Realizing that our 
data collection and analyses were limited by the fact that we obtained such a small amount of 
material in our HPLC fractions as a result of the HPLC columns readily available to us, we 
looked to take advantage of other available techniques that allowed us to with larger quantities at 
once.  To do this we again scaled up our extraction volume; our previous scale-up was from 
50ml cultures to 500ml cultures, this time we grew up and extracted 10-1L cultures of 6249 
according to our already established procedures.  Approximately 1.2 grams of crude extract was 
obtained from the 10L extraction. 
 Both 
1
H-NMR and LCMS data suggested our compound contained impurities that 
hampered structure elucidation.  With that in mind, we sought to again to improve separation 
while also trying to isolate more of our active compound.  Thin Layer Chromatography (TLC) 
had been tried and abandon early in the project as we were never able to observe any movement 
or banding patterns on the silica-backed plates.  Having tried an array of solvents (EtOH, MeOH, 
EtOAc, water, etc.) we abandoned the technique as we were losing valuable material.  However, 
after the success with our solvent system utilized for HPLC, we revisited TLC, taking advantage 
of those less polar solvents that worked well.  We were able to develop a TLC system (98:2 
hex:EtOAc) that showed nice movement and band separation of our 6249 crude extract.  With a 
new TLC system in hand, we chose to run our extract on the Biotage Isolera
TM
 Flash Purification 
System.  While HPLC was limited by the amount of sample that could be loaded at once, the 
biotage system allowed us to work with larger quantities.   
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In addition, the biotage can operate at higher flow rates, thereby greatly increasing the length of 
the run, which in turn decreases the amount of solvent required. 
 Using the crude extract obtained from our 10L extraction, we dissolved the extract (as 
much as possible) in CHCl3, MeOH, and EtOAc.  All of the extract did not dissolve; the portion 
that did was pipette off and the insoluble portion was set aside.  TLC was run on the dissolved 
portion using our 98 hex: 2 EtOAc system and the same banding pattern was observed.  The 
dissolved material was then filtered through PTFE syringe filters (Whatman, 25mm, 0.45m 
pore size) and evaporated to dryness.  After weighing (128mg), the dried, filtered sample was re-
dissolved in CHCl3 and run on the Biotage Isolera
TM
 Four unit using a SNAP KP-Sil 25g 
cartridge at a flow rate of 10min/ml on collect all.  After column equilibration, the sample was 
loaded and  run isocratic at 98% hexanes an 2% EtOAc for 5.5 Column Volumes (CV) followed 
by a 9.5 CV run of 95% hexanes to 5% EtOAc.  A final solvent ratio of 90:10 hex:EtOAc over 
14 CV was run.  Each fraction collected was first spotted on a TLC plated and stained to 
determine when and where material began eluting the column.  A total of 47 fractions were 
collected, with distinct spotting observed in fractions 25 – 28; faint spotting was observed in 
fractions 29 – 33.  Fractions, 22 – 42, were run on a TLC plate (to include those immediately 
before and after the fractions showing spots) using our established TLC system; those displaying 
single, identical bands were combined.  Fractions 27 and 28 were the only fractions showing a 
single band; as these bands were identical, fractions 27 and 28 were combined.  Fractions 25 and 
26, though not pure, were also combined as they displayed identical banding patterns.  The 
fractions (combined 25+26 and 27+28) were dried and weighed.  Fourteen milligrams was 
obtained in the combined fraction 25 (impure).  
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Twelve milligrams was contained in the combined fraction 27 which appeared to be pure on 
TLC.  Both fractions analyzed on 
1
H-NMR using CDCl3 (Fig 26 and 27) and submitted for 
antimalarial assay testing (data shown in Table 36).   
 
 
Figure 26: 
1
H-NMR of 6249 combined biotage fractions 25+26 
 
 
1
H-NMR of biotage fraction 25+26 confirms the presence of impurities (shown in gray in 
Fig. 26) as was seen on TLC.  Fraction 27+28, though it did contain water, appeared relatively 
pure on 
1
H-NMR (Fig. 27) as was the case with it was run on TLC; this looked to be our active 
compound.   
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Although fraction 27 appeared pure in TLC and 
1
H-NMR, it, along with fraction 25, was 
submitted to the antimalarial assay as a column fraction.  Pure fractions are required to be 
submitted with their structure, which in this case had not yet been elucidated. 
 
Figure 27: 
1
H-NMR of 6249 combined biotage fractions 27+28.  
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TABLE 36: ANTIPROTOZOAL SCREENING ASSAYS – Malaria Biotage Fraction Data Summary 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity 
(Vero) 
Sample Name IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
6249 Biotage 
fr.25 
NA - NA - NC 
6249 Biotage 
fr.27+28 
<528.8 >9.0 <528.8 >9.0 NC 
Concentrations:  4760, 1587, 528.8 ng/ml  
 NA = Inactive     
 NC = No Cytotoxicity     
 Selectivity Index (S.I.) = IC 50 (Vero Cells)/IC 50 (P. falciparum) 
   
 
 
 
 
 Return assay data for our biotage fractions showed that our activity was indeed contained 
in our combined fraction 27, of which, we had a total of ~11mg remaining.  Using a different 
separation technique, the active compound was again isolated and its activity was confirmed via 
bioassay. In addition, the biotage technique allowed us to isolate enough material to run a 
13
C-
NMR (Fig. 28) which, along with subsquent 2D NMR analyses (COSY, HMBC, and HSQC), 
aided greatly in our structure dereplication. 
 
 D6 W2 
 CQ <26.4 120 
ART <26.4 <26.4 
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Figure 28: 
13
C-NMR of 6249 combined biotage fractions 27+28. 
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CHAPTER VI 
 
THE RESEARCH PROJECT – Structure Dereplication 
 
6.1 Standard Comparison 
A total of 15 carbon signals were observed in the 
13
C-NMR spectrum (Figure 28), not 
including the solvent signals (CDCl3).  As we believed, from early NMR data, our compound to 
be a terpene, our carbon NMR data supports the possibility of a modified sesquiterpene.  The 
chemical shift at ~170ppm in the carbon spectrum seemed to indicate the presence of a carbonyl 
functionality. The carbon signals at = ~105, ~95, and ~80ppm indicate these carbons have at 
least one electronegative atom attached (likely oxygen).  The signal at = ~50ppm suggests a 
possible electronegative atom attached to an adjacent carbon.  Taking these observations, along 
those from previous 
1
H-NMR spectra, into account, artemisinin was used as a reference/standard 
to help dereplicate our structure as based on some of our signals, it was possible our compound 
was an artemisinin derivative.  Artemisinin is a sesquiterpene lactone and, like our compound, is 
active against P. falciparum malaria at sub-micromolar concentrations.   In addition, some of the 
signals observed in both the 
1
H-NMR (= 5.8ppm) and 13C-NMR (= ~170ppm and ~105ppm) 
of our compound would also be expected in artemisinin.   
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The proton at = 5.8ppm could correspond to the lone proton attached to the carbon bearing two 
oxygen atoms as it would be the most deshielded.  The lactone, with is the most deshielded, 
would produce a signal on 
13
C-NMR at around ~170ppm with three less shielded chemical shifts 
around ~80-100ppm corresponding to  carbons associated with the trioxane ring.  We took 
proton- and carbon-NMR spectra of artemisinin; they are presented in Figures 29 and 32 
respectively. 
 
 
Figure 29: 
1
H-NMR of artemisinin in CDCl3. 
 
 
1
H-NMR of artemisinin revealed chemical shifts similar to those observed for our active 
compound, namely the singlet at = ~5.8ppm and the multiplet at = ~3.4ppm.   
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Figure 30 shows stacked 
1
H-NMR spectra of artemisinin (top) and our compound isolated from 
6249 (bottom), while some of our signals are relatively weak, the similarities here are striking.  
The observation was even more pronounced when we superimposed the two spectra (Figure 31).  
In the superimposed spectra, our artemisinin reference is shown in teal and our isolated 
compound is displayed in maroon.   
 
Figure 30: Stacked 
1
H-NMR of artemisinin (top) and 6249 biotage fraction 27 (bottom). 
 
 
13
C-NMR of artemisinin (shown in Fig. 32) also revealed key similarities between it and 
our isolated compound.   As would be expected for artemisinin, the carbon signal for the lactone 
(position 9 on the structure) is the farthest downfield (= 172.14ppm) as it is the most 
deshielded; this signal is also observed in our isolated compound (= 172.06ppm).   
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Other signals to the left of/downfield from of solvent signals (= ~77ppm) in artemisinin can be 
rather easily assigned to its structure as well.  The carbon at position 13 would most likely 
correspond to the signal at around = 105ppm as it has two oxygen atoms attached, one of which 
is attached to another oxygen atom which results in the peroxide; the carbon at position 7, which 
is also attached to two oxygen atoms most likely corresponds to the signal at = 93ppm.  This 
would mean the signal at = 79ppm represents the carbon at position 2 which is deshielded by 
the single oxygen attached to it.  All of these signals are also observed in our compound isolated 
from the fungal endophyte 6249. 
 
 
Figure 31:
 1
H-NMR of biotage fraction 27 superimposed on that of artemisinin. 
87 
 
 When the 
13
C-NMR spectra of artemisinin and the isolated compound from 6249 were 
stacked (Fig.33), all of the chemical shifts observed for artemisinin (top) were also present in our 
compound (bottom). 
 
Figure 32: 
13
C-NMR of artemisinin in CDCl3. 
 
 Though the purity of our compound was not 100%, the 
1
H- and 
13
C-NMR spectra for our 
artemisinin reference were identical to the respective spectra obtain for our compound isolated 
from 6249. 
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6.2 Confirmation of Our Structure 
 
 While our 1D-NMR data was very convincing, it was imperative that our proposed 
structure be confirmed using 2D-NMR.  An HSQC (Heteronuclear Single Quantum Coherence), 
which correlates directly bonded carbon-proton nuclei, was run to determine which protons were 
bound to which carbons in our molecule.  The spectrum for this 2D experiment is presented in 
Figure 34; the carbon traces lies along the vertical axis while the proton trace lies along the 
horizontal axis. 
Figure 33: Stacked 
13
C-NMR of artemisinin (top) and 6249 biotage fraction 27. 
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Figure 34:  Two-dimensional HSQC spectrum of 6249 biotage fraction 27. 
 
 An enlarged version of the HSQC (Figure 35) revealed bond correlations between the 
carbon at ~12ppm and three protons at 1.25ppm.  The carbons at = ~20 and ~25ppm also show 
the attachment of three protons.  While the impurities make it difficult to determine with 
certainty, the carbons at  = 23.3, 24.7, 33.5, and 35.41ppm each appear to have two attached 
protons.  Only one proton is attached to the carbons with chemical shifts of 32.9, 35.7, ~45, ~50, 
and ~93ppm.  The carbon bearing the carbonyl and the two carbons linking the peroxide do not 
have protons attached to them.  The HMBC (Heteronuclear Multiple Bond Correlation) spectrum 
shown in Figure 36 identifies long range C-H couplings. 
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Figure 35: Enlarged HSQC spectrum of our isolated compound. 
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Figure 36: Two-dimensional HMBC spectrum of 6249 biotage fraction 27 with an enlargement. 
 
 
 
 
 
 
 
 
93 
 
CHAPTER VII 
 
THE RESEARCH PROJECT – Analyzing Artemisinin Production 
 
Once the activity of our fraction had again been confirmed, analytical testing methods 
were developed for our extracts.  Obtaining results from bioassay testing took an average of 4 
months per submission; while the assay testing was necessary for our bioassay-guided 
fractionation steps, it was not as critical once our active compound had been identified.  Once 
established, the analytical method would make it easier to identify artemisinin in our fungal 
extracts. 
Prior to the structural identification of our active compound, we tried analytical 
techniques like GC- and LCMS numerous times in an effort to obtain an analytical fingerprint 
for identification of our compound, but this was to no avail as it appeared that our compound was 
poorly ionized using various conditions.  Once our compound had been identified, we were able 
to go to the literature and develop an LCMS method using artemisinin as our reference standard.  
Our samples were run on an Agilent HP 1100 with Bruker micro-TOF using a C8 column 
(4.6mm x 150mm, 5, Phenomenex) with a 0.6ml/min flow rate.  The LC mobile phase started at 
20:80 MeOH:water (0.05% formic acid) and went to 100% MeOH over 12 minutes.  The MS 
was run in positive ion mode with electrospray ionization (ESI).   
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A source temperature of 200°C and a cone voltage of 90V were used.  The data for our 
artemisinin standard and isolate 6249 is shown Figures 37 and 38 below.  Our new analytical 
method allowed us to identify artemisinin production in our extractions without bioassay 
submission; in addition, we were able to quickly draw conclusion from other experiments 
conducted on our fungal endophytes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: LC-MS chromatogram of our artemisinin standard. 
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Figure 38: LC-MS chromatogram of our artemisinin isolated from 6249. 
 
7.1 Labeling Study 1/Growth on Other Media Types 
 7.1a. Attempt at 
13
C labeling 
 Once our active compound was identified as artemisinin, feeding studies were set up 
using 
13
C-labeled dextrose to try to incorporate a label into our compound.  To do this, PDB was 
prepared using the same ingredients according to the proportions on the label of our Difco 
manufactured brand.  The Difco PDB is listed to contain 20g dextrose (D-glucose) and 4g potato 
starch per liter of distilled water.  For the feeding studies, we prepared PDB using 18g dextrose, 
2g 
13
C-labeled dextrose (10% of total dextrose in the medium), and 4g potato starch per liter of 
distilled water.  Five 1L flasks, each containing our labeled media were inoculated with isolate 
6249 and incubated (30°C) with shaking (140 rpm) as previously described.   
96 
 
After 14 days of incubation, our fungal isolate showed no growth in the labeled media.  To 
determine if there was a problem with the label itself, we attempted to re-grow the organism 
without the label.  Using 50ml culture volumes, 6249 was inoculated in 2 flasks containing the 
Difco manufactured PDB and 4 flasks containing our PDB prepared according to the proportions 
listed on the label of the Difco brand.  Our prepared media contained 1g dextrose to 0.2g potato 
starch per 50ml flask.  The 6 cultures were again incubated with shaking at 30°C.  After 14 days, 
growth was observed in the two cultures grown in the Difco media, but no growth was observed 
in the cultures grown in the media we prepared ourselves.  It was determined that the labeled 
dextrose likely had no affect on the lack of growth observed from the feeding studies as the 
sample, although it grew well in the Difco brand, did not grow in the prepared media with or 
without the label present. 
 
 7.1b. Analyzing growth on other media types 
 After making the observation that our organism grew differently in different media, or in 
the case the same medium prepared differently, we decided to test the growth and production of 
our fungal isolate on 5 different types of broth media.  Malt Extract Broth (MEB), Yeast Malt 
Broth (YMB), Sabouraud Dextrose Broth (SDB), and Yeast Peptone Dextrose Broth (YPD) were 
all tested here, with PDB used as a control; all media used was manufactured by Difco. 
 MEB is comprised of malt extract, which is a source of carbon, protein, and other growth 
nutrients; the sugars maltose and dextrose, which serve as the organism’s energy and 
carbohydrate source respectively; and yeast extract, which is added as a source of vitamins and 
other cofactors essential for growth.  MEB is used for the cultivation of yeasts and molds. 
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 As the name implies, YM broth contains both yeast and malt extract.  The yeast extract 
provides vitamins and nutrients, which the malt extract provides a carbon and protein source for 
the organism.  In addition, peptone is added, providing a source of nitrogen and amino acids as 
well as another source of carbon.  Dextrose is also added as a carbon source.  YM can be used 
for no only cultivating yeasts and molds, but also for culturing bacterial microorganisms that are 
adapted to acidic environments. 
 SDB is also used to culture acidophiles in addition to molds and yeasts.  This medium 
contains peptic digests of animal tissue and pancreatic digests of casein to provide the required 
nitrogen and vitamin sources for growth of the organism; dextrose is added as an energy source. 
 YPD broth, prepared from yeast extract, peptone, and dextrose, is a general medium used 
to culture yeasts.  While dextrose provides a source of carbohydrates, yeast extract and peptone 
provides carbon and nitrogen sources as well as other vitamins and minerals. 
 PDB, as previously stated, contains potato starch and dextrose, both of which support the 
growth of yeasts and molds. 
 For the study, each medium was prepared according to its product label at a volume of 
250ml.  Prior to autoclaving, the broth media was dispensed in 25ml aliquots, into 25 x 100mm 
disposable culture tubes.  Six culture tubes were filled for each medium; 100ml of each medium 
remained.  After autoclaving and cooling all the media, five culture tubes for each represented 
medium was inoculated with fungal endophyte 6249 using sterile technique as previously 
described; the sixth culture tube for each medium was used as a blank control.  The 100ml broth 
for each medium that remained after culture tubes were filled was also inoculated with 6249.  All 
of the cultures were incubated at 30°C with shaking.   
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The flasks were shaken at 140rpm, while the culture tubes were shaken at 180rpm.  The cultures 
were observed daily to note how fast the organism grew in each medium.  If it observed that the 
organism grew faster in another medium, while still producing the active artemisinin metabolite, 
then it would be possible to decrease our 14 day growth period. 
 With inoculation day considered Day 0, no growth was observed for either media type on 
Day 1. Both MEB and YMB showed some turbidity on Day 2, indicating growth of the organism 
(Table 37).  The key difference between MEB and YMB, when compared to the other media 
used, is the presence of malt extract, an ingredient absent in the other media types.  By Day 3 all 
five media were showing signs of growth.  The cultures grown in PDB, YPD, and SDB were all 
slightly turbid whereas those grown in YMB and MEB showed significant growth (the red cells 
of the organism were clearly visible).  On Day 4 it was possible to see the actual cells in each 
media type; growth observations were no longer made after this point. 
TABLE 37: GROWTH OF 6249 ON A SERIES OF MEDIA 
 Day 
Growth 
Medium 
1 2 3 4 
PDB - - + ++ 
MEB - + ++ ++ 
SDB - - + ++ 
YMB - + ++ ++ 
YPD - - + ++ 
- No growth  + Some growth  ++ Significant growth 
 
 
As all of the samples were showing such significant growth, they were extracted on Day 
8 of the growth cycle.  The v/v EtOAc extractions proceeded as previously described, using the 
100ml cultures grown in the flasks.   
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After filtering, the cells were dried and weighed as a measure of cell production/growth; the dry 
weight for each growth medium is presented in Table 38. 
TABLE 38: MEASURED GROWTH FOR EACH MEDIUM 
Growth Medium Dry Cell Weight (mg) 
PDB 53.9 
MEB 112.0 
SBD 35.5 
YMB 87.1 
YPD 10.1 
 
 
As is indicated by the numbers, MEB and YM produced the most cell growth.  This coincided 
with daily growth observations in which the organism showed signs of growth within the first 
two days.  The crude extract obtained for each medium was analyzed on the LC-MS for 
production of artemisinin using our established method.  The data is presented in Figures 39 – 
43; our artemisinin standard is shown in Figure 44.  Scanning for a m/z of 277, artemisinin 
production was noted for extracts grown in SDB, MEB, and PDB. 
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Figure 39: LC-MS chromatogram of 6249 grown in PDB. 
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Figure 40: LC-MS chromatogram of 6249 grown in MEB. 
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Figure 41: LC-MS chromatogram of 6249 grown in SDB. 
 
103 
 
 
Figure 42: LC-MS chromatogram of 6249 grown in YMB. 
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Figure 43: LC-MS chromatogram of 6249 grown in YPD. 
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Figure 44: LC-MS chromatogram of our artemisinin standard. 
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 7.1c. Growth on Solid Media 
 In another effort to improve artemisinin production by the organism, growth of 6249 on 
various solid media was attempted.  We used the whole grains millet, grits, barley, and barley 
flakes; all obtained from Whole Foods Market (Memphis, TN), as our growth media.  One 
hundred grams of each whole gram was weighed out twice and placed in separate 500ml flasks 
for a total of 8 flasks; 20ml of distilled water was added to each flask.  The mouth of each flask 
was covered with foil and they were then autoclaved at 121°C for 15 minutes to sterilize the 
media.  In preparation for this study, 6249 was inoculated in 25ml of PDB contained in 25 x 
100mm culture tubes; ten tubes were inoculated.  These tubes were incubated at 30°C, with 
shaking (180rpm), for 7 days.  After & days of incubation, the cultures were used as our 
incoulum.  The 8 flasks containing the sterile grains were each inoculated with a 25ml inoculum 
of 6249.  As a replicate of each grain was inoculated; one of the flasks for each grain was kept at 
room temperature with ambient lighting while the other was wrapped completely in foil and kept 
at room temperature in a dark cabinet.  The samples were checked weekly for growth, but after 2 
months there was still no growth of 6249 on our solid media.  It was concluded that, as 
endophytic microorganisms, these fungi are adapted for growth in moist environments. 
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CHAPTER VIII 
 
 
 
ANALYSES OF ADDITIONAL FUNGI SHOWN TO POSSESS ANTIMALARIAL 
ACTIVITY 
 
 
8.1 Fungal Isolate DC038 
 
 8.1a. Growth vs. Production 1 
 After experiencing problems with our 6249 isolate and being unable to revive it from its 
original voucher sample, we began to look at some of our other isolates that had shown 
promising results in antimalarial assays (Figures 10 – 23).  Specifically we were looking for 
artemisinin production in these organisms as well. 
 Isolate DC038, isolated from the same host organism as 6249, was already shown to have 
antimalarial activity.  Additionally, using our established analytical method, previous extractions 
of this organism had been shown to produce artemisinin. 
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Figure 45: LC-MS chromatogram of our artemisinin standard. 
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Figure 46: LC-MS chromatogram of fungal extract DC038. 
 
   
 After confirming the production of artemisinin by DC038, we continued our work, using 
this organism to look at growth versus artemisinin production.  For this study, we sought to 
monitor growth and evaluate production every 24 hours, with data collected in triplicate.  
Therefore 42 culture tubes (3 per day x 14 days), each containing 25ml of PDB were inoculated 
with a 10l inoculum of DC038.  The tubes were incubated in the shaker at 30°C and 180rpm.  
Three blank culture tubes (media only) were incubated also as controls.  Growth was evaluated 
by drying and measuring the pre-weighed filtered paper used to filter the cells before extraction.  
Growth data is presented in Figure 47.   
Production of artemisinin was measured by LC-MS analysis of our daily crude extracts using our 
previously described method of detection.  This data is presented in Figures 48 – 51. 
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Figure 47: Monitored daily growth of DC038. 
 
 
 
Figure 48: LC-MS for DAY 1 of artemisinin production study. 
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Figure 49: LC-MS for DAY 2 of artemisinin production study. 
 
 What we noticed around Day 4 was that while growth itself was minimal, when we 
looked at the LC-MS chromatograms, we seemed to have artemisinin production.  As production 
should not be observed without growth of the organism, we co-injected artemisinin with our 
Day1 – 4 extracts to determine if what we were seeing was indeed artemisinin.  As can be seen in 
Figure 52, while the retention times are very close, two distant peaks were observed, indicating 
artemisinin was not being produced at this point.  On day 8, as can be seen in Figure 53, we 
observed our first artemisinin product.  Overlapping the growth and production graphs (Figure 
54), we see that production commenced within a day of fungal growth.  The Growth vs. 
Production study lasted 14 days; we noted, from the production graph (Figure 53) that while 
growth seemed to be on the decline, it was difficult to tell the direction in which our artemisinin 
production was going.  For this reason we decided to repeat the study, extending it to 21 days. 
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Figure 50: LC-MS for DAY 3 of artemisinin production study. 
 
 
Figure 51: LC-MS for DAY 4 of artemisinin production study. 
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Figure 52: LC-MS for artemisinin co-injection with extract of Days 1 – 4. 
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Figure 53: Monitored daily artemisinin production for DC038. 
 
 
 
Figure 54: Overlap of 14 day growth and production data for DC038. 
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 8.1b. Growth vs. Production 2 
 
 As it was difficult to tell the direction of our artemisinin production at the end of the 14 
day growth v. production study previously conducted, the study was  repeated extending its 
length to 21 days.  In addition, the size of the DC038 inoculum was increased from 10l to 1ml. 
Growth and evaluate production were again monitored every 24 hours, with data collected in 
triplicate.  A total of 63 culture tubes (3 per day x 21 days), each containing 25ml of PDB were 
inoculated with a 1ml inoculum of DC038.  The tubes were incubated in the shaker at 30°C and 
180rpm.  Three blank culture tubes (media only) were incubated also as controls.  Growth was 
again evaluated by drying and measuring the pre-weighed filtered paper used to filter the cells 
before extraction.  Growth data is presented in Figure 55.   
 
 
Figure 55:   Monitored daily growth of DC038 
 
 Our growth chart shows noticeable growth of our sample on Day 1, 24 hours post 
inoculation; growth was not observed until Day 7 in the 14 day study.   
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This can most likely be attributed to the 100-fold increase in the inoculum volume.  In the 14 day 
growth v. production study, a 10l volume of DC038 was inoculated into our culture tubes 
contain 25ml PDB compared to a 1ml volume used in the 21 day study.   
LC-MS analyses of our 14 day growth v. production data showed a media component of 
mass 277, identical to our extracted ion, we therefore worked to develop another method for 
identification of our compound.  LC-MS analysis of the crude extracts from our 21 day growth v. 
production study was conducted on a Waters Micromass ZQ System with an attached photodiode 
array (PDA) detector.  A Prodigy, 5, ODS column (100mm x 4.6mm) was used.  The mobile 
phase consisted of a water (1% formic acid) and acetonitrile (CH3CN) gradient. At a flow rate of 
0.5ml/min., the mobile phase started with 28% water and 72% CH3CN and ran isocratic for 14 
minutes.  It then went to 100% CH3CN in 2 minutes.  The injection volume was 30l; the mass 
spectrometer was operated in electrospray positive ion mode.  A needle voltage of 3.5kV was 
used with a source temperature and cone voltage of 120°C and 70V respectively.  MestReNova 
7.1 (© 2011 Mestrelab Research S.L.) Molecule Match software was used to analysis our 
spectral data.  The software parameters were set using a MS tolerance of 0.1 Da with a score 
threshold of 0.80.  The spectra were matched to four molecules corresponding to artemisinin as 
well as the presumed artemisinin precursors amorpha-4,11-diene, artemisinic acid, and 
dihydroartemisinic acid.  In addition to scanning for the molecular ion peak at m/z = 283 
([M+H]
+
), positive adducts at m/z = 300 ([M+NH4]
+
); m/z = 305 ([M+Na]
+
); and m/z = 321 
([M+K]
+
) were also searched as research shows these adducts to be common for some molecules 
being ionized in positive ion mode
104
.  Spectra corresponding to artemisinin with H
+
, NH4
+
, and 
K
+
 adducts are presented in Figure 56 – 58, no artemisinin-Na+ adducts were observed using this 
method.   
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Production of artemisinin and the related precursors was determined using the MS purity values 
reported by the Molecule Match feature for the molecule of interest.  The MS purity is the 
proportion of the molecular ion intensity resulting from our match relative to the total intensity 
of the spectrum. 
 
Figure 56:  Artemisinin-H
+
 molecular ions were detected at ~2 minutes. 
 
Just as in the shorter study, artemisinin production commensed the after growth is 
observed.  As can be seen in the production graph (Figure 59) for the 21 day study, artemisinin 
production is first observed around Day 2.  In the first study we noticed that production followed 
somewhat of an up and down pattern from day to day.  
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This scenario was also observed in the second study.  The graph shows that artemisinin 
production was erratic.  After the 16
th
 day, a steady decline in production is noted. 
 
Figure 57:  Artemisinin-NH4
+
 adducts were also detected ~2 minutes.
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Figure 58:  Artemisinin-K
+
 adducts were detected at ~3 minutes. 
 
 
Figure 59: Observed artemisinin production by DC038 in 21 day Growth v. Production Study. 
 
-0.02 
-0.01 
0 
0.01 
0.02 
0.03 
0.04 
0.05 
0.06 
0.07 
0.08 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 A
ye
ra
ge
 M
S 
P
u
ri
ty
 o
b
se
rv
e
d
 in
 
sp
e
ct
ru
m
 
Day 
Production of Artemisinin 
Avg. MS Purity of artemisinin 
120 
 
 The erratic pattern of artemisinin production was intriguing; and for this reason, we chose 
to also look for artemisinin precursors in our spectral data.  Utilizing the Mass Plugin of 
MestReNova 7.1 (Mestrelab Research), we were able to identify artemisinin along with its 
precursors in our acquired spectra.  The Molecule Match feature is useful both molecule 
confirmation and metabolite identification; it automatically matches your spectral data to 
particular molecule(s) of interest.  Structures that do not match any part of the acquired spectrum 
are returned as “No match”.  Not only does Molecule Match provide retention times and scan 
numbers for the matched molecules, the software also provides a similarity value, a match score, 
and MS purity information.  The similarity value can range from 0 to 1 (with 1 being ideal); it 
represents a comparison of the computed molecular ion cluster for a structure with that acquired 
from the data set.  The match score is a combination of the similarity value and the observed 
molecular isotope cluster chromatogram (MICC) value, where the MICC is defined as the sum of 
mass chromatograms of all significant peaks in the isotope cluster
105
.  As previously mentioned, 
the MS purity describes the proportion of the molecular ion intensity resulting from our match 
relative to that of the total spectrum. 
 Figure 60 shows the production of artemisinin (yellow/orange) as well as its precursors 
amorpha-4,11-diene (red/pink) and dihydroartemisinic acid (purple).  It should be noted that 
while the presumed precursor artemisinic acid was used in our Molecule Match search, its 
structure did not match with any spectra in our data set. 
 As previously mentioned, amorpha-4,11-diene is an early precursor in the biosynthesis of 
artemisinin
66, 67, 68, 69
.  In our precursor production analyses using Molecule Match, it was the 
most abundant of our searched molecules.  Amorpha-4,11-diene, which has a molecular weight 
of approximately 204, was detected as a sodium adduct of m/z = 227.  
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Spectral data for this molecule is presented in Figure 61.  Production of amorpha-4,11-diene was 
first observed in Day 1 and it continued throughout the 21 day process (Figure 60); however, 
around Day 19 it did begin to show a steady decline.   
Dihydroartemisinic acid, believed by many in the field to be the final precursor in the 
biosynthesis of artemisinin
72, 73, 76, 81, 82
, was first detected on Day 2 of our study with production 
peaking at Day 6.  It appeared as an M + 1 molecular ion at m/z = 237 (Figure 62).  Like 
artemisinin production, the production of dihydroartemisinic acid began to slow down around 
Day 16.  Artemisinic acid, previously thought to be the final precursor for artemisinin 
biosynthesis
77, 78, 79
, was not detected in any of our samples using the Molecule Match search.  
As seen in Figure 60, artemisinin itself appears to be the least abundant of the three molecules 
detected; with the production pattern of all three almost paralleling each other (i.e., up and down 
on the same days).  While no dihydroartemisinic acid was detected after Day 16, trace amounts 
our artemisinin was detected through Day 21. 
 
Figure 60: Production of artemisinin and its precursors amorpha-4,11-diene and 
dihydroartemisinic acid by DC038 in 21 day Growth v. Production study.  Artemisinic acid, a 
presumed precursor of artemisinin, was not detected. 
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Figure 61: Amorpha-4,11-diene-Na
+
 adducts were detected at ~21 minutes. 
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Figure 62: Dihydroartemisinic acid-H
+
 molecular ions were detected at ~28 minutes. 
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8.2 Light/Dark Study 
 In an effort to determine if artemisinin production by our endophytes was enzymatic or 
proceeded through a photooxidation-type reaction as is believed to be the case in artemisinin 
production by the plant Artemisia annua, we evaluated production under light and dark 
conditions.  Production of artemisinin from isolates grown in the dark would be indicative of 
enzyme activity. 
 For this study, eight culture tubes (25mm x 100mm), each containing 25ml of PDB, were 
inoculated with DC038.  Prior to incubation, four of the cultures were completely wrapped in 
aluminum foil to simulate a dark environment.  The other four cultures were left unwrapped and 
allowed to incubate under our normal lighting conditions.  The eight tubes, plus a blank (media 
only) tube for each condition (light and dark), were incubated at 30°C and allowed to shake at 
180rpm for 14 days (Figure 63). 
 
 
 
 
 
 
 
Figure 63: Incubation of Light/Dark Study samples. 
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After the prescribed 14 day incubation period, the samples were extracted in EtOAc (v/v), 
according to our established extraction procedure.  Samples grown in dark-simulated conditions 
were extracted using the same dark conditions (Figure 64).  Our samples grown under normal 
lighting conditions were extracted using our standard extraction conditions. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: Extraction setup simulating our dark conditions. 
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 LC-MS data from our initial Light/Dark Study was collected on the Agilent HP 1100 
system with Bruker micro-TOF using a C8 column (4.6mm x 150mm, 5, Phenomenex) at a 
flow rate of 0.6ml/min.  As in our earlier experiments, the LC mobile phase ran from 20:80 
MeOH:water (0.05% formic acid) to 100% MeOH over 12 minutes.  The MS was run in positive 
mode with ESI; a source temperature of 200°C and a cone voltage of 90V were used.  The 
collected spectra and chromatograms for the light and dark treatments are shown in Figure 65.  
As this work was conducted prior to our discovery of a media component with the same mass, 
our extracted ion here is 277.  Both the spectra and chromatograms were seemingly identical for 
the light and dark samples, indicating the possibility of artemisinin production through 
enzymatic activity.  However, after the aforementioned discovery of a media component with an 
identical mass as our extracted ion, we decided to repeat the light/dark work.   
 This study was replicated in larger scale.  Sample DC038 was inoculated into 12-2800ml 
Fernbach flasks, each containing 1L PDB; 6 of the cultures were incubated at 30°C, with shaking 
(160rpm) under ambient lighting (Figure 66) while the other 6 cultures were wrapped in 
aluminum foil to simulate our dark conditions (Figure 67).  The cultures grown in the dark were 
also incubated at 30°C and allowed to shake at 160rpm.  As controls, a blank (media only) flask 
for each treatment condition was also incubated with the test flasks.  All samples were incubated 
for 14 days.  After the 14 day incubation period, the samples were filtered and thrice extracted in 
EtOAc (v/v) as previously described.  The samples grown under normal lighting conditions were 
extracted under ambient lighting as well.  In keeping with our dark simulated conditions, those 
samples grown in the dark were extracted using glassware wrapped in aluminum foil as had been 
done on the small-scale experiment (Figure 68), with the hood lights turned off. 
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Figure 65:  Comparison of data collected from light and dark treatments of DC038 in 
Light/Dark Study #1. 
 
 This time, in an effort to get rid of some of the noise in our spectra, both the light 
(1.3487g) and dark (1.4882g) crude extracts were fractionated using Alltech Extract-Clean Silica 
SPE Coulumns (2g, 15ml).  Fractions were eluted on a gradient of 100 hexanes to 100 DCM in 
increments of 10 (Scheme 2). 
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Figure 66: DC038 samples and light control after incubation with ambient lighting.  
 
 
 
Figure 67: DC038 samples and dark control after incubation with no light.  
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Figure 68: Extraction of Dark DC038 samples using the dark simulated conditions pictured here. 
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Scheme 2:  Elution Wash Scheme of DC038 Light and Dark Samples. 
DC038 Light crude extract 
(1.3487g) 
100 Hex 
(531.9mg obtained) 
9:1 Hex: DCM 
(155.0mg) 
8:2 Hex: DCM 
(54.9mg) 
7:3 Hex: DCM 
(6.7mg) 
6:4 Hex: DCM 
(1.6mg) 
1:1 Hex: DCM 
(3.3mg) 
4:6 Hex: DCM 
(3.5mg) 
3:7 Hex: DCM 
(5.3mg) 
2:8 Hex: DCM 
(5.8mg) 
1:9 Hex: DCM 
(7.3mg)  
100 DCM 
(11.4mg) 
DC038 Dark crude extract 
(1.4882g) 
100 Hex 
(850.7mg obtained) 
9:1 Hex: DCM 
(143.6mg) 
8:2 Hex: DCM 
(8.8mg) 
7:3 Hex: DCM 
(1.5mg) 
6:4 Hex: DCM 
(1.1mg) 
1:1 Hex: DCM 
(0.7mg) 
4:6 Hex: DCM 
(4.1mg) 
3:7 Hex: DCM 
(1.4mg) 
2:8 Hex: DCM 
(1.4mg) 
1:9 Hex: DCM 
(1.9mg)  
100 DCM 
(5.9mg) 
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LC-MS analysis of the fractions from the second Light/Dark study was conducted on a 
Waters Micromass ZQ System with an attached photodiode array (PDA) detector.  As described 
previously, a Prodigy, 5, ODS column (100mm x 4.6mm) was used.  The mobile phase, which 
was identical to that used for our 21 day growth v. production work, consisted of a water (1% 
formic acid) and acetonitrile (CH3CN) gradient with a flow rate of 0.5ml/min.  The mobile phase 
started with 28% water and 72% CH3CN and ran isocratic for 14 minutes.  It then went to 100% 
CH3CN in 2 minutes.  The injection volume was 30l; the mass spectrometer was operated in 
electrospray positive ion mode.  A needle voltage of 3.5kV was used with a source temperature 
and cone voltage of 120°C and 70V respectively.  The MestReNova 7.1 (© 2011 Mestrelab 
Research S.L.) Molecule Match software was again used for our spectral analyses.  The software 
parameters were set using a MS tolerance of 0.1 Da with a score threshold of 0.80.  To determine 
with fraction(s) contained artemisinin, the spectrum for each fraction was scanned for the 
molecular ion peak at m/z = 283 ([M+H]
+
), as well as the previously noted positive adducts at 
m/z = 300 ([M+NH4]
+
); m/z = 305 ([M+Na]
+
); and m/z = 321 ([M+K]
+
).  The spectra were only 
matched to artemisinin in this study.  Spectral data corresponding to the light and dark fractions 
shown to contain artemisinin is presented in Figure 69.  Dark and Light control samples were 
also run and analyzed using the same parameters. 
Our artemisinin only showed matches to the 9:1 Hex: DCM fractions in both the DC038 
Dark and DC038 Light samples.  Shown in the top spectrum of Figure 69, our artemisinin 
appears in our dark sample as a potassium adduct, m/z = 321 ([M+K]
+
), at approximately 3 
minutes.  As seem in the bottom spectrum (Figure 69), artemisinin appears in at approximately 2 
minutes as a sodium adduct, m/z = 305 ([M+Na]
+
).   
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Figure 69: Comparison of DC038 Light and Dark spectra. 
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It should be noted that peaks corresponding to the molecular ion, m/z = 283 ([M+H]
+
), in 
addition to adducts at m/z = 300 ([M+NH4]
+
); m/z = 305 ([M+Na]
+
); and m/z = 321 ([M+K]
+
) for 
both the light and dark 9:1 fractions.  However, these peaks were very minor, with the only the 
most intense matches depicted in Figure 69. 
The observation of artemisinin in both our DC038 samples grown using ambient lighting 
conditions and those grown in no light conditions is significant as current literature concludes 
that the conversion of the final precursor (widely accepted as dihydroartemisinic acid) proceeds 
non-ezymatically through via photooxidative reactions
83, 84
.  Given that production of artemisinin 
proceeded in absence of light in our dark samples, it appears possible that a series of enzymatic, 
rather than light-mediated, reactions are responsible for conversion of the final precursor into 
artemisinin. 
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8.3 Another Attempt at Labeling 
 
 Our previous attempt at labeling failed as we discovered our organism (6249) did not 
grow at all in the media (PDB) when we prepared it ourselves according to the ingredients listed 
on the label of the Difco manufactured PDB.  In our second attempt, we chose to supplement the 
Difco manufactured PDB with our 
13
C-labeled D-glucose (CIL).  As one liter of Difco PDB 
contains 20g of dextrose, the 25ml cultures used in this study were calculated to contain 0.5g of 
dextrose.  Ten culture tubes, each containing 25ml of PDB (Difco), were inoculated with a 1ml 
inoculum of sample DC038 and incubated, with shaking (180rpm), at 30°C.  Two blank tubes 
(media only) were also incubated as controls.  After five days of incubation, eight of the 10 tubes 
inoculated with DC038 were supplemented with 
13
C-labeled dextrose according to the scale 
outlined below. 
- 50mg (representing 10% of the total dextrose in the 25ml PDB culture) 
- 100mg or 20% of the total dextrose 
- 150mg or 30% of the total dextrose 
- 200mg or 40% of the total dextrose 
A replicate for each treatment condition was prepared, resulting in two tubes supplemented for 
each treatment.  The two remaining tubes that were inoculated with DC038 were used as non-
labeled controls.  All of the tubes were placed back in the shaker and allowed to incubate (30°C) 
for nine more days; they were then extracted (v/v) in EtOAc according to our standard extraction 
protocol.  LC-MS analyses of the crude extracts obtained from this study were performed on a 
Waters Micromass ZQ System with an attached photodiode array (PDA) detector using a 
Prodigy, 5, ODS column (100mm x 4.6mm).   
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The mobile phase consisted of a water (1% formic acid) and acetonitrile (CH3CN) gradient at a 
flow rate of 0.5ml/min.  The mobile phase started with 28% water and 72% CH3CN and ran 
isocratic for 14 minutes.  It then went to 100% CH3CN in 2 minutes.  The injection volume was 
30l; the mass spectrometer was operated in electrospray positive ion mode.  A needle voltage of 
3.5kV was used with a source temperature and cone voltage of 120°C and 70V respectively.  
While spectral data confirmed the presence of artemisinin in our extracts, the data showed no 
incorporation of our 
13
C-label into the compound (Figures 70a – d). 
 
 
Figure 70a:  DC038 isolate supplemented with 10% 
13
C-glucose shows production of 
artemisinin [M + NH4]
+
, but no incorporation of the label. 
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Figure 70b:  DC038 isolate supplemented with 20% 
13
C-glucose shows production of 
artemisinin [M + NH4]
+
, but no incorporation of the label. 
 
 Spectral data shows the production of artemisinin, however no mass peaks corresponding 
to our 
13
C-glucose label were observed.  Based on the proposed biosynthesis of artemisinin from 
the five carbon IPP and DMAPP precursors (see Section 3.2), we expected to see our mass (with 
adduct(s)), plus ~5 Da, ~10 Da, and/or ~15 Da.  The multiples of 5 correspond to the mass 
difference between 
12
C and 
13
C (1.0034 amu).  Our work here is based on the assumption that the 
glucose already contained in the media was depleted as the samples were allowed to incubate 5 
days prior to supplementation with our labeled glucose.  Because of this assumption it is logical 
to assume that the 5 carbon IPP and DMAPP precursors would be biosynthesized using only 
labeled carbons; hence the reason we searched for our mass plus multiples of five. 
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Figure 70c:  DC038 isolate supplemented with 30% 
13
C-glucose shows production of 
artemisinin [M + NH4]
+
, but no incorporation of the label. 
 
While it is possible that our labeled peaks were overlooked, as would be the case if our 
precursors contained less than 5 labeled carbons, it is equally likely the labeled carbons were just 
not incorporated into the molecule.  Due to the fact that glucose is a ubiquitous source of energy 
for many cellular processes, another labeled precursor should be considered for this study. 
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Figure 70d:  DC038 isolate supplemented with 40% 
13
C-glucose shows production of 
artemisinin [M + NH4]
+
, but no incorporation of the label. 
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CHAPTER IX 
 
 
 
CONCLUSIONS 
 
 
 Malaria is one of the most severe public health problems in developing countries; it is 
widespread in tropical and subtropical regions with the vast majority of deaths occurring in sub-
Saharan Africa.  Though there are several parasites known to cause malaria, P. falciparum 
accounts for the most fatalities.  
 Early strategies for combating malaria and its spread focused on mosquito control.  
Anopheles mosquitoes act as a vector for the plasmodium parasites, transferring the parasite to 
human hosts with each blood meal.  Drainage systems were developed to relieve stagnant waters 
that served as breeding grounds for mosquitoes.  This evolved into sanitation programs designed 
to clear the streets of all trash and anything that could collect water; these programs had sporadic 
success from city to city.  However, much success was met with the introduction of 
pesticides/insecticides like DDT, in the early 1900s. 
 Aside from mosquito control efforts, the first drug agent used in the treatment of malaria 
was quinine.  Quinine was isolated around 1820 and it remains an important and effective 
treatment for malaria in most parts of the world.  Antimalarial drug development flourished post 
World War I in large part due to the lack of available quinine during the war.   
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Chloroquine, a synthetic drug ignored for years because of toxicity concerns, was the most 
successful of the drugs developed during this time.  Artemisinin, isolated from the leaves of 
Artemisia annua, was discovered by a Chinese scientist in the early 1970s.  It was found to be 
just as effective as quinine and chloroquine at clearing malaria parasites. 
 Drug resistance continues to be a significant problem in the fight against malaria.  
Resistance limits the efficacy of even the most potent drugs, rendering once effective drugs 
obsolete.  Resistance to chloroquine was noted within a decade of its release, with subsequently 
released antimalarials meeting a similar fate.  Resistance to all classes of antimalarials is now 
common, with the exception of the artemisinins.  What is clear from the history of antimalarial 
agents is that plant-derived drugs, most notably quinine and artemisinin, have far outlived their 
synthetic counterparts.  It is for this reason that the work presented here is so noteworthy.  With 
nothing to go on, the biological activity of fungal these endophytes was evaluated and found to 
be simply amazing. 
 We were supplied with fungal endophytes isolated from host organisms in the continental 
U.S.  Each isolate was grown and extracted in EtOAc (v/v).  After assay submission, several 
isolates were shown to have antimalarial, antileishmania, and/or antimicrobial activities.  The 
sample showing antileishmania activity was discounted as were did not trust the validity of the 
assay itself; additionally we did not focus our attention on those isolates possessing antimicrobial 
activities because many fungi are known to produce antibiotics.  However, those isolates found 
to have antimalarial activity were of particular interest to us because there was nothing in the 
literature pertaining to the antimalarial properties associated with fungal organisms. 
 Upon confirmation of our activity data, we sought to isolate our active compound(s).   
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After numerous attempts, using various separation techniques, we were able to isolate our active 
compound.  It was first successfully isolated using HPLC; though we were not able to isolate 
enough material for further analyses using this method.  However using the biotage, we collected 
enough of our compound to run both a proton and carbon NMR, from which we were about to 
elucidate our structure.  Once our compound, artemisinin, had been isolated and its activity again 
confirmed via bioassay we were able to develop analytical methods for identification of 
artemisinin in our crude extracts.  This was imperative as receiving biological assay data took 
months and was greatly slowing our progress; our analytical method allowed us to obtain 
valuable information quickly. 
 Using our analytical method, we worked to optimize our fractionation and isolation 
methodologies.  We analyzed growth of our organism versus production of our active metabolite 
in one study while looking at production of our active metabolite as well as other known 
precursors in other.  We attempted large-scale adaptation of our liquid-fermentation procedures 
in an effort to produce sufficient quantities of our product; growth on solid media was also 
evaluated, but was of no avail as our tested isolate showed no growth.  Multiple attempts at 
labeling using 
13
C-labeled dextrose also proved futile as our label was not incorporated into our 
artemisinin product.  Though this was initially viewed as a setback, we realized that because 
glucose is used for so many cellular processes, it is probably not the best precursor to use for this 
particular application.  We concluded that using a labeled precursor farther down the 
biosynthetic pathway, like mevalonate, would likely produce more favorably results. 
 Another important aspect of our analytical method was that it enabled us to quickly 
analyze some of our other fungal endophytes shown, through previous assay screening, to have 
antimalarial activities.   
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Using our standard growth and extraction methodologies, along with our analytical method 
established for running samples on our Waters Micromass ZQ System we were able to identify 
artemisinin production, using the Molecule Match software (MestReNova 7.1 © 2011 Mestrelab 
Research S.L.), in several of our other isolates.  Isolates DC019, DC299, DC001, DC347, and 
DC7 were shown to produce artemisinin (Figures 71 – 75).  Figure 71 shows our artemisinin 
molecular ion, [M+H]
+
, present in isolate DC019; Figures 72 and 73 shows that our molecular 
ion complex is also present in fungal isolates DC299 and DC001 respectively.  Figure 74 
confirms the presence of artemisinin in isolate DC347; here are compound appears as a 
[M+NH4
+
] adduct.  Artemisinin production was also observed in isolate DC7, as can be seen by 
the presence of our [M+H]
+
 molecular ion in Figure 75. 
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Figure 71: MS spectrum of DC019 showing molecule match with artemisinin. 
 
 The very small quantities of artemisinin produced by our isolates limited our NMR 
analyses.  Spectral data for nearly all of our crude extracts revealed on small quantities of 
artemisinin; fractionation of these crude extracts yielded even less material as we were never 
able to isolate all of the artemisinin present in the crude extract.  However, we were able to 
isolate either artemisinin in our fractions obtained from isolate DC7 for 
1
H-NMR analysis.  The 
spectrum obtained from proton NMR analysis is presented in Figure 76.  Though it is obvious 
from the spectrum that the sample itself is not pure, the signal observed at =5.8 is indicative of 
artemisinin. 
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Figure 72: MS spectrum of DC299 showing molecule match with artemisinin. 
 
 The importance of this work stems from the desperate need for new antimalarial agents 
and/or sources of said agents. Despite the shrinking pool of effective antimalarial therapies, new 
antimalarial drug development has only occurred in the last decade.  As a result, almost all 
antimalarials on the market were synthesized or discovered during the efforts around the two 
world wars.  While the endophytic replationships between plants and fungi are seemingly 
ubiquitous in nature, to date, these relationships are not well understood.  Because of the 
abundance of fungal endophytes, these organisms offer great potential for drug discovery as little 
work has gone into the study of these symbiotic interactions.  
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Figure 73: MS spectrum of DC001 showing molecule match with artemisinin. 
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Figure 74: MS spectrum of DC347 showing molecule match with artemisinin. 
147 
 
Figure 75: MS spectrum of DC7 showing molecule match with artemisinin. 
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Figure 76: 
1
H-NMR spectrum obtained for DC7 fractions 6+7. 
 
 This project began simply as a new student trying to learn her way around the lab; upon 
obtaining our initial bioassay data, we have made tremendous progress in developing this 
project.  While we have confirmed the production of artemisinin by a number of our fungal 
endophytes, we continue our efforts to increase product yields.  In addition to labeling 
experiments using other labeled precursors, future work includes the isolation and identification 
of genes and/or gene clusters involved in the biosynthetic pathway for artemisinin production by 
our orgainisms. Our work here is noteworthy because for decades, Artemisia annua has been the 
only source of artemisinin, limiting its supply which in turn increases it cost.  Production of 
artemisinin by another organism lends success to a search that has gone on for decades. 
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